ATE88501T1 - Rekombinante dns-expressionsvektoren. - Google Patents

Rekombinante dns-expressionsvektoren.

Info

Publication number: ATE88501T1
Authority: AT; Austria
Prior art keywords: vectors; expression vectors; recombinant dna; dna expression; hcmv
Prior art date: 1987-07-23

Application number

AT88906008T

Other languages

English (en)

Inventor

Christopher Robert Bebbington

Original Assignee

Celltech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-07-23

Filing date

1988-07-22

Publication date

1993-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10621156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE88501(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-07-22 Application filed by Celltech Ltd filed Critical Celltech Ltd

1993-05-15 Application granted granted Critical

1993-05-15 Publication of ATE88501T1 publication Critical patent/ATE88501T1/de

Links

239000013604 expression vector Substances 0.000 title abstract 2
108020004511 Recombinant DNA Proteins 0.000 title 1
239000013598 vector Substances 0.000 abstract 3
108020004414 DNA Proteins 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
108091026890 Coding region Proteins 0.000 abstract 1
241000701024 Human betaherpesvirus 5 Species 0.000 abstract 1
108700002232 Immediate-Early Genes Proteins 0.000 abstract 1
108091026898 Leader sequence (mRNA) Proteins 0.000 abstract 1
239000003623 enhancer Substances 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Detection And Correction Of Errors (AREA)
Enzymes And Modification Thereof (AREA)

AT88906008T 1987-07-23 1988-07-22 Rekombinante dns-expressionsvektoren. ATE88501T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB878717430A GB8717430D0 (en)	1987-07-23	1987-07-23	Recombinant dna product
PCT/GB1988/000602 WO1989001036A1 (en)	1987-07-23	1988-07-22	Recombinant dna expression vectors
EP88906008A EP0323997B1 (de)	1987-07-23	1988-07-22	Rekombinante dns-expressionsvektoren

Publications (1)

Publication Number	Publication Date
ATE88501T1 true ATE88501T1 (de)	1993-05-15

Family

ID=10621156

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT88906008T ATE88501T1 (de)	1987-07-23	1988-07-22	Rekombinante dns-expressionsvektoren.

Country Status (7)

Country	Link
US (2)	US5591639A (de)
EP (1)	EP0323997B1 (de)
JP (1)	JP2505268B2 (de)
AT (1)	ATE88501T1 (de)
DE (1)	DE3880468T2 (de)
GB (1)	GB8717430D0 (de)
WO (1)	WO1989001036A1 (de)

Families Citing this family (772)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1341423C (en) *	1984-10-31	2003-03-04	Paul A. Luciw	Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US5089496A (en) *	1986-10-31	1992-02-18	Schering Corporation	Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
GB8927722D0 (en) *	1989-12-07	1990-02-07	British Bio Technology	Proteins and nucleic acids
US6750325B1 (en)	1989-12-21	2004-06-15	Celltech R&D Limited	CD3 specific recombinant antibody
GB9209993D0 (en)	1992-05-08	1992-06-24	Munn Edward A	Vaccines
NZ261259A (en)	1993-01-12	1996-12-20	Biogen Inc	Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
US6323185B1 (en) *	1993-04-23	2001-11-27	The United States Of America As Represented By The Department Of Health And Human Services	Anti-viral guanosine-rich oligonucleotides and method of treating HIV
US5567604A (en) *	1993-04-23	1996-10-22	Aronex Pharmaceuticals, Inc.	Anti-viral guanosine-rich oligonucleotides
US6288042B1 (en)	1993-04-23	2001-09-11	Aronex Pharmaceuticals, Inc.	Anti-viral guanosine-rich tetrad forming oligonucleotides
US6562333B1 (en)	1993-06-14	2003-05-13	Schering Corporation	Purified mammalian CTLA-8 antigens and related reagents
IT1262545B (it) *	1993-10-25	1996-07-02	Menarini Ricerche Sud S P A A	Sistema di espressione per linee cellulari eucariotiche
GB9415319D0 (en) *	1994-07-29	1994-09-21	Medical Res Council	HSV viral vector
US7597886B2 (en)	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US5641665A (en) *	1994-11-28	1997-06-24	Vical Incorporated	Plasmids suitable for IL-2 expression
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
CA2227867A1 (en) *	1995-07-19	1997-02-06	Michael E. Hogan	Anti-viral guanosine-rich oligonucleotides
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
AU3027797A (en) *	1996-05-24	1998-01-05	Novartis Ag	Recombinat rna 3'-terminal phosphate cyclases and production methods thereof
CA2279488A1 (en) *	1997-02-04	1998-08-06	Aronex Pharmaceuticals, Inc.	Anti-viral guanosine-rich tetrad forming oligonucleotides
US5990091A (en)	1997-03-12	1999-11-23	Virogenetics Corporation	Vectors having enhanced expression, and methods of making and uses thereof
GB9715064D0 (en) *	1997-07-17	1997-09-24	Ppl Therapeutics Scotland Ltd	Protein expression
US6517843B1 (en)	1999-08-31	2003-02-11	Merial	Reduction of porcine circovirus-2 viral load with inactivated PCV-2
IL142680A0 (en) *	1998-10-19	2002-03-10	Powderject Vaccines Inc	Minimal promoters and uses thereof
US7109003B2 (en)	1998-12-23	2006-09-19	Abgenix, Inc.	Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et)	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
HRP20130077A2 (hr)	1998-12-23	2013-07-31	Pfizer Inc.	Humana monoklonalna protutjela za ctla-4
US7279568B2 (en)	1998-12-31	2007-10-09	Viromed Limited	Highly efficient eukaryotic expression vector comprising an exogenous transcription regulatory element
KR20000046969A (ko) *	1998-12-31	2000-07-25	이선경	이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
PT1141297E (pt)	1999-01-11	2010-01-06	Schering Corp	Citoquinas de mamíferos relacionadas com a interleucina-17. polinucleótidos que as codificam. utilizações
EP2357192A1 (de)	1999-02-26	2011-08-17	Human Genome Sciences, Inc.	Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
US7605238B2 (en)	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
CN102766210B (zh)	1999-08-24	2015-07-08	E.R.施贵宝&圣斯有限责任公司	人ctla-4抗体及其应用
ES2301498T3 (es) *	1999-12-21	2008-07-01	Merial	Composiciones y vacunas que contienen uno o mas antigenos de cryptosporidium parvum y de otro patogeno enterico.
EP1274720A4 (de)	2000-04-12	2004-08-18	Human Genome Sciences Inc	Albumin enthaltende fusionsproteine
US7700359B2 (en)	2000-06-02	2010-04-20	Novartis Vaccines And Diagnostics, Inc.	Gene products differentially expressed in cancerous cells
WO2003057926A1 (en)	2002-01-08	2003-07-17	Chiron Corporation	Gene products differentially expressed in cancerous breast cells and their methods of use
US20030031675A1 (en)	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
WO2001096528A2 (en)	2000-06-15	2001-12-20	Human Genome Sciences, Inc.	Human tumor necrosis factor delta and epsilon
AU2001268427B2 (en)	2000-06-16	2007-03-29	Glaxosmithkline Intellectual Property Limited	Antibodies that immunospecifically bind to blys
AU2001268716A1 (en)	2000-06-23	2002-01-08	Maxygen, Inc.	Novel chimeric promoters
GB0020685D0 (en)	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
US20020099183A1 (en) *	2000-08-23	2002-07-25	Pluschkell Stefanie Beate	Process for the preparation of neutrophil inhibitory factor
AU1994402A (en)	2000-11-28	2002-06-11	Mediummune Inc	Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
JP4336498B2 (ja)	2000-12-12	2009-09-30	メディミューン，エルエルシー	延長した半減期を有する分子ならびにその組成物および用途
PA8535501A1 (es)	2001-01-05	2003-07-28	Pfizer	Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US20020108132A1 (en) *	2001-02-02	2002-08-08	Avigenics Inc.	Production of a monoclonal antibody by a transgenic chicken
US7176300B2 (en) *	2001-03-30	2007-02-13	Avigenics, Inc.	Avian lysozyme promoter
WO2002079470A1 (en) *	2001-03-30	2002-10-10	King A Christie	Disease-specific promoter chimeras for gene expression
AU2002255995A1 (en) *	2001-03-30	2002-10-15	Avigenics, Inc.	Avian lysozyme promoter
US7541512B2 (en) *	2001-03-30	2009-06-02	Synageva Biopharma Corp.	Avians containing a lysozyme promoter transgene
DE60236646D1 (de)	2001-04-13	2010-07-22	Human Genome Sciences Inc	Anti-VEGF-2 Antikörper
US7256257B2 (en)	2001-04-30	2007-08-14	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
JP2005519580A (ja)	2001-05-16	2005-07-07	アルバートアインシュタインカレッジオブメディシンオブイエシバユニバーシティ	非ヒト動物由来のヒト抗肺炎球菌抗体
CN100594935C (zh)	2001-05-25	2010-03-24	人体基因组科学有限公司	免疫特异性结合trail受体的抗体
US7166467B2 (en) *	2001-07-23	2007-01-23	Senesco Technologies, Inc.	Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
US7550650B2 (en) *	2001-09-18	2009-06-23	Synageva Biopharma Corp.	Production of a transgenic avian by cytoplasmic injection
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US20100333219A1 (en) *	2001-11-30	2010-12-30	Synageva Biopharma Corp.	Methods of protein production using ovomucoid regulatory regions
US7294507B2 (en) *	2001-11-30	2007-11-13	Avigenics, Inc.	Ovomucoid promoters and methods of use
US7335761B2 (en) *	2001-11-30	2008-02-26	Avigenics, Inc.	Avian gene expression controlling regions
US6875588B2 (en)	2001-11-30	2005-04-05	Avigenics, Inc.	Ovomucoid promoter and methods of use
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
US20080194481A1 (en)	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
WO2003073910A2 (en)	2002-03-01	2003-09-12	Bayer Corporation	Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
ES2329565T3 (es)	2002-03-01	2009-11-27	Siemens Healthcare Diagnostics Inc.	Pruebas para monitorear pacientes con cancer, basadas en los niveles de analito de dominio extracelular (ecd) del factor receptor del crecimiento epidermico (egfr),solo o en combinacion con otros analitos,en muestras de fluidos corporales.
US7135562B2 (en) *	2002-03-14	2006-11-14	University Of Cincinnati	Avian iFABP gene expression controlling region
US20040241723A1 (en) *	2002-03-18	2004-12-02	Marquess Foley Leigh Shaw	Systems and methods for improving protein and milk production of dairy herds
GB0207533D0 (en)	2002-04-02	2002-05-08	Oxford Glycosciences Uk Ltd	Protein
JP2005535572A (ja)	2002-04-12	2005-11-24	メディミューン，インコーポレーテッド	組換え抗インターロイキン−９抗体
ES2384168T3 (es)	2002-04-12	2012-07-02	Medarex, Inc.	Procedimientos de tratamiento usando anticuerpos CTLA-4
NZ536475A (en)	2002-05-24	2008-06-30	Schering Corp	Neutralizing human anti-igfr antibody
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
ES2544527T3 (es)	2002-07-31	2015-09-01	Seattle Genetics, Inc.	Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
CA2495121A1 (en)	2002-08-10	2004-02-19	Yale University	Nogo receptor antagonists
JP2006516883A (ja)	2002-09-19	2006-07-13	アメリカ合衆国	Ｐ．アリアシポリペプチド、ユウガイサシチョウバエポリペプチド、および使用法
SI1551876T1 (sl)	2002-10-16	2011-07-29	Purdue Pharma Lp	Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo
KR20110017020A (ko)	2002-10-17	2011-02-18	젠맵 에이/에스	Ｃｄ20에 대한 인간 모노클로날 항체
DE60327366D1 (de)	2002-10-29	2009-06-04	Fundacao Oswaldo Cruz	Lutzomyia longipalpis-polypeptide und verwendungsverfahren
DE10254601A1 (de)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
SI1585546T1 (sl)	2002-12-30	2008-12-31	Biogen Idec Inc	KIM-1 antagonisti in uporaba za moduliranje imunskega sistema
MXPA05007615A (es)	2003-01-21	2005-09-30	Bristol Myers Squibb Co	Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
CN1980571A (zh) *	2003-01-24	2007-06-13	阿维季尼克斯股份有限公司	禽类及禽蛋中表达的外源蛋白质
EP1594955B1 (de) *	2003-02-14	2012-04-11	Biogen Idec MA Inc.	Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle
WO2004073737A1 (en)	2003-02-19	2004-09-02	Merial Limited	Vaccination or immunization using a prime-boost regimen against brsv, bhv-1, bvdv, bpi-3
DK1594542T3 (da)	2003-02-20	2010-10-11	Seattle Genetics Inc	Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
EP2390352A1 (de)	2003-03-18	2011-11-30	Quantum Genetics Ireland Limited	Systeme und Methoden zur Erhöhung der Milchproduktion bei Tieren
PL2248899T3 (pl)	2003-03-19	2015-10-30	Biogen Ma Inc	Białko wiążące receptor nogo
KR20110094361A (ko)	2003-04-11	2011-08-23	메디뮨 엘엘씨	재조합 ｉｌ９ 항체 및 그의 용도
EP1631590B1 (de)	2003-04-23	2011-07-27	Medarex, Inc.	Humanisierte antikörper gegen interferon-alpha-rezeptor-1 (ifnar-1)
US7468273B2 (en)	2003-05-01	2008-12-23	Meial Limited	Canine GHRH gene, polypeptides and methods of use
US9708410B2 (en)	2003-05-30	2017-07-18	Janssen Biotech, Inc.	Anti-tissue factor antibodies and compositions
WO2005010040A1 (en)	2003-07-15	2005-02-03	Barros Research Institute	Eimeria tenella antigen for immunotherapy of coccidiosis
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
US20050048617A1 (en)	2003-08-18	2005-03-03	Medimmune, Inc.	Humanization of antibodies
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
EA010056B1 (ru)	2003-10-10	2008-06-30	Паудерджект Вэксинс, Инк.	Конструкции нуклеиновых кислот
SI1680141T1 (sl)	2003-11-04	2010-12-31	Novartis Vaccines & Diagnostic	Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen
ES2346978T3 (es)	2003-11-04	2010-10-22	Novartis Vaccines And Diagnostics, Inc.	Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
WO2005044307A2 (en)	2003-11-04	2005-05-19	Chiron Corporation	Methods of therapy for b cell-related cancers
JP4746552B2 (ja)	2003-11-04	2011-08-10	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
EP3434275A1 (de)	2003-11-06	2019-01-30	Seattle Genetics, Inc.	Auf die verwendung von auristatin-konjugaten mit antikörpern basierter nachweis für krebszellen
US20050214316A1 (en)	2003-11-13	2005-09-29	Brown Thomas P	Methods of characterizing infectious bursal disease virus
ES2399050T3 (es)	2003-12-10	2013-03-25	Medarex, Inc.	Anticuerpos contra interferón alfa y sus usos
KR101374514B1 (ko)	2003-12-10	2014-03-13	메다렉스, 인코포레이티드	Ｉｐ―１０ 항체 및 그의 용도
JP4943161B2 (ja)	2003-12-23	2012-05-30	ジェネンテック，インコーポレイテッド	新規抗ｉｌ１３モノクローナル抗体での癌の処置
MX370489B (es)	2004-01-09	2019-12-16	Pfizer	Anticuerpos contra madcam.
EP2857418B1 (de)	2004-02-06	2017-07-26	University of Massachusetts	Antikörper gegen Clostridium difficile Toxine und ihre Verwendung
JP5010923B2 (ja)	2004-02-09	2012-08-29	ヒューマンジノームサイエンシーズ，インコーポレイテッド	アルブミン融合蛋白質
EP1718770B1 (de)	2004-02-19	2011-05-25	The Governors of the University of Alberta	Leptinpromotor-polymorphismen und verwendungen davon
JP4705026B2 (ja)	2004-03-19	2011-06-22	ジェノミディア株式会社	血管内皮増殖促進遺伝子
EP1786463A4 (de)	2004-03-26	2009-05-20	Human Genome Sciences Inc	Antikörper gegen nogo-rezeptor
EP1755673B1 (de)	2004-04-12	2014-07-23	MedImmune, LLC	Anti-il-9-antikörperformulierungen und deren verwendung
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
KR20150041193A (ko)	2004-06-21	2015-04-15	메다렉스, 엘.엘.시.	인터페론 알파 수용체 1 항체 및 그의 용도
KR101239542B1 (ko)	2004-06-24	2013-03-07	바이오겐 아이덱 엠에이 인코포레이티드	탈수초화를 수반하는 병의 치료
RU2342159C2 (ru)	2004-07-16	2008-12-27	Пфайзер Продактс Инк.	Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
EP2476427B1 (de)	2004-08-02	2018-01-17	Zenyth Operations PTY. Ltd.	Verfahren zur Behandlung von Krebs mit einem VEGF-B-Antagonisten
WO2006017673A2 (en)	2004-08-03	2006-02-16	Biogen Idec Ma Inc.	Taj in neuronal function
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
WO2006047639A2 (en)	2004-10-27	2006-05-04	Medimmune, Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060099144A1 (en)	2004-11-08	2006-05-11	Schering Corporation	Tumor association of MDL-1 and methods
CA2631240A1 (en) *	2004-12-03	2006-06-08	Xoma Technology Ltd.	Methods and materials for expression of a recombinant protein
US20080064862A1 (en) *	2004-12-29	2008-03-13	Avigenics, Inc.	Transgene expression in a avians
HUE025945T2 (en)	2005-02-15	2016-07-28	Univ Duke	Anti-CD19 antibodies and their applications in oncology
GB0504587D0 (en) *	2005-03-05	2005-04-13	Ml Lab Plc	Vectors comprising guinea pig CMV regulatory elements
ATE440956T1 (de) *	2005-03-05	2009-09-15	Millipore Corp	Neue regulatorische elemente enthaltende vektoren
LT2620450T (lt)	2005-03-08	2019-02-11	Pfizer Products Inc.	Anti-ctla-4 antikūnų kompozicijos
EP1869192B1 (de)	2005-03-18	2016-01-20	MedImmune, LLC	Rahmenmischung von antikörpern
EP3312196B1 (de)	2005-03-23	2019-07-17	Genmab A/S	Antikörper gegen cd38 zur behandlung von multiplem myelom
US8323645B2 (en)	2005-03-24	2012-12-04	Millennium Pharmaceuticals, Inc.	Antibodies that bind OV064 and methods of use therefor
EP1871418B1 (de)	2005-04-19	2014-03-19	Seattle Genetics, Inc.	Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung
EP1877075A4 (de)	2005-04-25	2008-07-30	Pfizer	Antikörper gegen myostatin
RS51324B (sr)	2005-04-25	2010-12-31	Merial Ltd.	Vakcine protiv nipah virusa
NZ562234A (en)	2005-04-26	2009-09-25	Pfizer	P-cadherin antibodies
AU2006244445B2 (en)	2005-05-05	2013-04-18	Duke University	Anti-CD19 antibody therapy for autoimmune disease
PL2161336T5 (pl)	2005-05-09	2017-10-31	Ono Pharmaceutical Co	Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
PL1889065T3 (pl)	2005-05-18	2013-12-31	Novartis Ag	Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
PE20061444A1 (es)	2005-05-19	2007-01-15	Centocor Inc	Anticuerpo anti-mcp-1, composiciones, metodos y usos
KR20080025174A (ko)	2005-06-23	2008-03-19	메디뮨 인코포레이티드	응집 및 단편화 프로파일이 최적화된 항체 제제
CA2612241C (en)	2005-07-01	2018-11-06	Medarex, Inc.	Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
JP5171621B2 (ja)	2005-07-07	2013-03-27	シアトルジェネティックス，インコーポレイテッド	フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
CA2902070A1 (en)	2005-07-08	2007-01-18	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
WO2007019541A2 (en)	2005-08-08	2007-02-15	Onconon, Llc.	Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US20080241184A1 (en)	2005-08-25	2008-10-02	Jules Maarten Minke	Canine influenza vaccines
KR101536506B1 (ko)	2005-09-07	2015-07-14	암젠 프레몬트 인코포레이티드	액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
EP1762575A1 (de)	2005-09-12	2007-03-14	Ganymed Pharmaceuticals AG	Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
NZ566395A (en)	2005-09-26	2012-03-30	Medarex Inc	Human monoclonal antibodies to CD70
WO2007053732A2 (en)	2005-11-01	2007-05-10	Mayo Foundation For Medical Education And Research	Promoter polymorphisms of the blys gene and use in diagnostic methods
PT2500030E (pt)	2005-11-04	2015-09-24	Genentech Inc	Uso de inibidores da via do complemento para tratar doenças oculares
WO2007056161A1 (en)	2005-11-04	2007-05-18	Biogen Idec Ma Inc.	Methods for promoting neurite outgrowth and survival of dopaminergic neurons
CA2629522A1 (en)	2005-11-14	2007-05-18	Merial Limited	Gene therapy for renal failure
US7771995B2 (en)	2005-11-14	2010-08-10	Merial Limited	Plasmid encoding human BMP-7
EP1790664A1 (de)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
EP2805971A1 (de)	2005-11-28	2014-11-26	ZymoGenetics, Inc.	IL-21-Antagonisten
EP1965827B1 (de)	2005-12-02	2015-02-25	Biogen Idec MA Inc.	Behandlung von entmyelinisierenden erkrankungen
CN101325971A (zh)	2005-12-07	2008-12-17	米德列斯公司	Ctla-4抗体剂量递增方案
EP1960434B1 (de)	2005-12-08	2012-07-11	Medarex, Inc.	Humane monoklonale antikörper gegen fucosyl-gm1 und verfahren zur anwendung von anti-fucosyl-gm1
CA2632828C (en)	2005-12-12	2012-07-10	F. Hoffmann-La Roche Ag	Antibodies against amyloid beta with glycosylation in the variable region
US7745158B2 (en) *	2005-12-14	2010-06-29	Kimberly-Clark Worldwide, Inc.	Detection of secreted aspartyl proteases from Candida species
CA2640423C (en)	2006-01-27	2016-03-15	Biogen Idec Ma Inc.	Nogo receptor antagonists
WO2007103469A2 (en)	2006-03-06	2007-09-13	Aeres Biomedical Ltd.	Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP3167900B1 (de)	2006-03-29	2018-11-21	Merial Limited	Impfstoff gegen streptokokken
JP5514539B2 (ja)	2006-03-31	2014-06-04	メダレックス・リミテッド・ライアビリティ・カンパニー	ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
US8071323B2 (en)	2006-04-07	2011-12-06	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Human monoclonal antibodies that bind human insulin like growth factors and their use
GEP20125628B (en)	2006-04-21	2012-09-10	Novartis Ag	Pharmaceutical compositions containing antagonist anti-cd40 antibody
US7862821B2 (en)	2006-06-01	2011-01-04	Merial Limited	Recombinant vaccine against bluetongue virus
GB0611116D0 (en)	2006-06-06	2006-07-19	Oxford Genome Sciences Uk Ltd	Proteins
US20080112888A1 (en)	2006-06-30	2008-05-15	Schering Corporation	Igfbp2 biomarker
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
JP5638804B2 (ja)	2006-08-04	2014-12-10	アストラゼネカアクチボラグ	ＥｒｂＢ２に対する抗体
US9505823B2 (en)	2006-08-07	2016-11-29	TEV A Biopharmaceuticals USA, Inc.	Albumin-insulin fusion proteins
EP2046834B9 (de)	2006-08-11	2013-04-10	Ono Pharmaceutical Co., Ltd.	Monoklonale antikörper gegen stromal derived factor-1 (sdf-1-)
WO2008017126A1 (en)	2006-08-11	2008-02-14	Csl Limited	Treatment of pulmonary disease conditions
EA021255B1 (ru)	2006-08-28	2015-05-29	Киова Хакко Кирин Ко., Лимитед	Антагонистические моноклональные антитела человека, специфичные в отношении light человека
KR20090088852A (ko)	2006-09-05	2009-08-20	메다렉스, 인코포레이티드	골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
AU2007302448C1 (en)	2006-09-26	2019-02-14	Genmab A/S	Combination treatment of CD38-expressing tumors
ES2625798T3 (es)	2006-10-02	2017-07-20	E. R. Squibb & Sons, L.L.C.	Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
EP2064335A4 (de)	2006-10-16	2011-03-30	Medimmune Llc	Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
DK2068922T3 (da)	2006-10-19	2012-10-08	Csl Ltd	Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
EP2068921B1 (de)	2006-10-19	2014-07-09	CSL Limited	Hochaffine antikörper-antagonisten des interleukin-13-rezeptors alpha 1
US8202967B2 (en)	2006-10-27	2012-06-19	Boehringer Ingelheim Vetmedica, Inc.	H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
AU2007334264A1 (en)	2006-11-15	2008-06-26	Medarex, Inc.	Human monoclonal antibodies to BTLA and methods of use
EP2097097B1 (de)	2006-12-01	2018-05-30	E. R. Squibb & Sons, L.L.C.	Antikörper, insbesondere menschliche antikörper, die an cd22 binden und deren verwendung
DK2099823T4 (da)	2006-12-01	2022-05-09	Seagen Inc	Målbindingsmiddelvarianter og anvendelser deraf
EP2687232A1 (de)	2006-12-06	2014-01-22	MedImmune, LLC	Verfahren zur Behandlung von systemischem Lupus erythematodes
EP2104501B1 (de)	2006-12-13	2014-03-12	Merck Sharp & Dohme Corp.	Verfahren zur krebsbehandlung mit igf1r-inhibitoren
CL2007003622A1 (es)	2006-12-13	2009-08-07	Medarex Inc	Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AU2007333098A1 (en)	2006-12-14	2008-06-19	Medarex, Inc.	Human antibodies that bind CD70 and uses thereof
RU2493167C2 (ru)	2006-12-18	2013-09-20	Дженентек, Инк.	АНТИТЕЛА-АНТАГОНИСТЫ ПРОТИВ Notch3 И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С Notch3 ЗАБОЛЕВАНИЙ
PT2099826E (pt)	2007-01-05	2014-01-09	Univ Zuerich	Anticorpo anti-beta-amilóide e suas utilizações
US8128926B2 (en)	2007-01-09	2012-03-06	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
CN101636168B (zh)	2007-01-09	2013-05-29	比奥根艾迪克Ma公司	Sp35抗体及其用途
NZ578816A (en)	2007-02-02	2012-06-29	Biogen Idec Inc	Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
WO2008101184A2 (en)	2007-02-16	2008-08-21	The Board Of Trustees Of Southern Illinois University	Arl-1 specific antibodies
US8685666B2 (en)	2007-02-16	2014-04-01	The Board Of Trustees Of Southern Illinois University	ARL-1 specific antibodies and uses thereof
JP5357782B2 (ja)	2007-02-21	2013-12-04	バクシネックスインコーポレーティッド	抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
US8551484B2 (en)	2007-02-21	2013-10-08	University Of Massachusetts	Human antibodies against hepatitis C virus (HCV) and uses thereof
EP2447719B1 (de)	2007-02-26	2016-08-24	Oxford BioTherapeutics Ltd	Proteine
WO2008104803A2 (en)	2007-02-26	2008-09-04	Oxford Genome Sciences (Uk) Limited	Proteins
EP1970384A1 (de)	2007-03-14	2008-09-17	Ganymed Pharmaceuticals AG	Monoklonale Antikörper zur Krebsbehandlung
US20100209434A1 (en)	2007-03-30	2010-08-19	Medimmune, Llc	Antibody formulation
WO2008134046A1 (en)	2007-04-27	2008-11-06	Genentech, Inc.	Potent, stable and non-immunosuppressive anti-cd4 antibodies
AU2007352618B2 (en)	2007-05-02	2013-07-18	Boehringer Ingelheim Animal Health USA Inc.	DNA plasmids having improved expression and stability
EP2703011A3 (de)	2007-05-07	2014-03-26	MedImmune, LLC	Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
DK3072525T3 (en)	2007-05-14	2018-04-30	Astrazeneca Ab	PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
EP1997832A1 (de)	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
WO2009097006A2 (en)	2007-08-10	2009-08-06	Medarex, Inc.	Hco32 and hco27 and related examples
PE20090993A1 (es)	2007-08-29	2009-07-08	Sanofi Aventis	Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
EP2190469B1 (de)	2007-09-04	2015-02-25	Compugen Ltd.	Polypeptide und polynukleotide und ihre verwendung als zielmolekül zur herstellung von arzneimitteln und biologika
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EP2050764A1 (de)	2007-10-15	2009-04-22	sanofi-aventis	Neues polyvalentes bispezifisches Antikörperformat und Verwendung
WO2009052588A1 (en)	2007-10-26	2009-04-30	Csl Limited	Cytokine muteins
PT2222697E (pt)	2007-11-01	2013-02-15	Perseid Therapeutics Llc	Polipeptídeos imunossupressores e ácidos nucleicos
CN101951954A (zh)	2007-11-02	2011-01-19	诺瓦提斯公司	调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法
BRPI0819195A2 (pt)	2007-11-05	2017-05-23	Medimmune Llc	métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento.
KR101811965B1 (ko)	2007-11-07	2017-12-22	셀덱스 쎄라퓨틱스, 인크.	인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
ES2566963T3 (es)	2007-11-21	2016-04-18	Oregon Health & Science University	Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
US8003325B2 (en) *	2007-11-30	2011-08-23	Mayo Foundation For Medical Education And Research	Polymorphisms of the BLyS gene and use in diagnostic methods
EP3103813A1 (de)	2007-12-07	2016-12-14	ZymoGenetics, Inc.	Anti-humane il-21 monoklonale antikörper
DK2222706T4 (en)	2007-12-14	2016-11-21	Novo Nordisk As	Antibodies that bind to NKG2D and its use
US9605035B2 (en)	2008-01-10	2017-03-28	Research Development Foundation	Vaccines and diagnostics for the ehrlichioses
ES2613963T3 (es)	2008-01-18	2017-05-29	Medimmune, Llc	Anticuerpos manipulados con cisteína para conjugación específica de sitio
MX2010008083A (es)	2008-01-25	2010-12-20	Univ Aarhus	Inhibicion de exositios selectivos de actividad papp-a contra igfbp-4.
AU2009212442C1 (en)	2008-02-05	2014-07-17	Bristol-Myers Squibb Company	Alpha 5 - beta 1 antibodies and their uses
CN101952454B (zh)	2008-02-08	2014-06-04	米迪缪尼有限公司	具有减弱的Fc配体亲和性的抗IFNAR1抗体
EP2252317B1 (de)	2008-02-15	2014-04-09	Tufts University	Behandlung von makuladegeneration
ES2456296T3 (es)	2008-03-27	2014-04-21	Zymogenetics, Inc.	Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
CN102076865B (zh)	2008-05-02	2016-03-16	西雅图基因公司	用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
US8603808B2 (en)	2008-05-08	2013-12-10	Merial Limited	Leishmania vaccine using sand fly salivary immunogen
JP2011527572A (ja)	2008-07-09	2011-11-04	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Ｌｉｎｇｏ抗体または断片を含む組成物
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR101442323B1 (ko)	2008-09-07	2014-09-25	글라이코넥스 인코포레이티드	항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
EP2166021A1 (de)	2008-09-16	2010-03-24	Ganymed Pharmaceuticals AG	Monoklonale Antikörper zur Krebsbehandlung
JP5933975B2 (ja)	2008-11-12	2016-06-15	メディミューン，エルエルシー	抗体製剤
CN102271704A (zh)	2008-11-28	2011-12-07	梅里亚有限公司	重组禽流感疫苗及其用途
EP2865689A1 (de)	2008-12-08	2015-04-29	Compugen Ltd.	FAM26F Polypeptide und Polynukleotide und Verwendungen davon als Arzneimittel-Target zur Herstellung von Arzneimitteln und Biologika
WO2010069603A1 (en)	2008-12-19	2010-06-24	Neurimmune Therapeutics Ag	Human anti-alpha-synuclein autoantibodies
EP2382238A1 (de)	2008-12-31	2011-11-02	Biogen Idec MA Inc.	Anti-lymphotoxin-antik?rper
CA2750581A1 (en)	2009-01-21	2010-07-29	Oxford Biotherapeutics Ltd.	Pta089 protein
US20100192236A1 (en) *	2009-01-28	2010-07-29	University Of South Carolina	Modulation of Delta Opioid Receptor Expression
WO2010093993A2 (en)	2009-02-12	2010-08-19	Human Genome Sciences, Inc.	Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
ES2963717T3 (es)	2009-02-20	2024-04-01	Astellas Pharma Inc	Métodos y composiciones para el diagnóstico y tratamiento del cáncer
PT2403878T (pt)	2009-03-05	2017-09-01	Squibb & Sons Llc	Anticorpos completamente humanos específicos a cadm1
WO2010111180A1 (en)	2009-03-24	2010-09-30	Teva Biopharmaceuticals Usa, Inc.	Humanized antibodies against light and uses thereof
WO2010112034A2 (en)	2009-04-02	2010-10-07	Aarhus Universitet	Compositions and methods for treatment and diagnosis of synucleinopathies
CN103585643A (zh)	2009-04-03	2014-02-19	梅里亚有限公司	运载新城疫病毒的禽疫苗
EP3009454A3 (de)	2009-04-20	2016-10-19	Oxford Bio Therapeutics Limited	Antikörper spezifisch gegen cadherin-17
US9062116B2 (en)	2009-04-23	2015-06-23	Infinity Pharmaceuticals, Inc.	Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US8715657B2 (en)	2009-04-27	2014-05-06	Novartis Ag	Therapeutic antibodies binding IL12Rβ1
CA2993053A1 (en)	2009-04-27	2010-11-04	Novartis Ag	Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
US20100284977A1 (en) *	2009-04-28	2010-11-11	University Of South Carolina	Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters
KR20120088550A (ko)	2009-05-04	2012-08-08	애보트 리서치 비.브이.	증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체
PL2427212T3 (pl)	2009-05-08	2018-02-28	Vaccinex, Inc.	Przeciwciała anty cd-100 i sposoby ich zastosowania
WO2010135742A1 (en)	2009-05-22	2010-11-25	Merial Limited	Antibiotic-free plasmid
CA2766405A1 (en)	2009-06-22	2011-01-13	Medimmune, Llc	Engineered fc regions for site-specific conjugation
LT2769737T (lt)	2009-07-20	2017-06-26	Bristol-Myers Squibb Company	Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
IN2012DN00863A (de)	2009-07-31	2015-07-10	Medarex Inc
WO2011021146A1 (en)	2009-08-20	2011-02-24	Pfizer Inc.	Osteopontin antibodies
TWI627281B (zh)	2009-09-02	2018-06-21	百靈佳殷格翰家畜藥品公司	降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
WO2011029823A1 (en)	2009-09-09	2011-03-17	Novartis Ag	Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
JP5785550B2 (ja)	2009-09-15	2015-09-30	シーエスエル、リミテッド	神経疾患の処置方法
US9540426B2 (en)	2009-10-06	2017-01-10	Bristol-Myers Squibb Company	Mammalian cell culture processes for protein production
EP2488553B1 (de)	2009-10-12	2015-06-17	Pfizer Inc.	Krebsbehandlung
EP2470569A1 (de)	2009-10-13	2012-07-04	Oxford Biotherapeutics Ltd.	Antikörper gegen epha10
MX366890B (es)	2009-10-23	2019-07-30	Millennium Pharm Inc	Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
US20120282177A1 (en)	2009-11-02	2012-11-08	Christian Rohlff	ROR1 as Therapeutic and Diagnostic Target
US20120277144A1 (en)	2009-11-04	2012-11-01	Henricus Johannes Duckers	Novel compounds for modulating neovascularisation and methods of treatment using these compounds
EP2322555A1 (de)	2009-11-11	2011-05-18	Ganymed Pharmaceuticals AG	Antikörper spezifisch für Claudin 6 (CLDN6)
RU2675997C2 (ru)	2009-11-11	2018-12-25	Ганимед Фармасьютикалз Аг	Антитела, специфичные к клаудину 6 (cldn6)
US9428586B2 (en)	2009-12-01	2016-08-30	Compugen Ltd	Heparanase splice variant
AR079767A1 (es)	2009-12-28	2012-02-15	Merial Ltd	Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo
NZ602278A (en)	2010-03-12	2014-12-24	Biolex Therapeutics Inc	Bluetongue virus recombinant vaccines and uses thereof
EP2547365A1 (de)	2010-03-17	2013-01-23	Abbott Research B.V.	Anti-ngf-antikörperzusammensetzungen
EP2371864A1 (de)	2010-03-23	2011-10-05	Ganymed Pharmaceuticals AG	Monoklonale Antikörper zur Krebsbehandlung
NZ602892A (en)	2010-04-13	2014-08-29	Celldex Therapeutics Inc	Antibodies that bind human cd27 and uses thereof
EA201291065A1 (ru)	2010-04-16	2013-03-29	Байоджен Айдек Ма Инк.	Антитела против vla-4
EP2569337A1 (de)	2010-05-14	2013-03-20	Rinat Neuroscience Corp.	Heterodimere proteine sowie verfahren zu ihrer herstellung und aufreinigung
EP2580243B1 (de)	2010-06-09	2019-10-16	Genmab A/S	Antikörper gegen menschliches cd38
SMT201700547T1 (it)	2010-06-15	2018-01-11	Genmab As	Coniugati di farmaco anticorpo umano contro il fattore tissutale
EP2404936A1 (de)	2010-07-06	2012-01-11	Ganymed Pharmaceuticals AG	Krebstherapie mittels CLDN6-zielgerichteter Antikörper im lebenden Organismus
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
WO2012021891A2 (en)	2010-08-13	2012-02-16	Tufts University	Compositions, kits and methods for treatment of complement-related disorders
WO2012022734A2 (en)	2010-08-16	2012-02-23	Medimmune Limited	Anti-icam-1 antibodies and methods of use
US20130224191A1 (en)	2010-08-27	2013-08-29	Robert A. Stull	Notum protein modulators and methods of use
WO2012030720A1 (en)	2010-08-31	2012-03-08	Merial Limited	Newcastle disease virus vectored herpesvirus vaccines
EP2611832B1 (de)	2010-09-02	2017-11-29	Vaccinex, Inc.	Anti-cxcl13-antikörper und verfahren zu ihrer verwendung
WO2012031273A2 (en)	2010-09-03	2012-03-08	Stem Centrx, Inc.	Novel modulators and methods of use
SG10201912092VA (en)	2010-09-09	2020-02-27	Pfizer	4-1bb binding molecules
WO2012035518A1 (en)	2010-09-17	2012-03-22	Compugen Ltd.	Compositions and methods for treatment of drug resistant multiple myeloma
UA112062C2 (uk)	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
JP2013543384A (ja)	2010-10-05	2013-12-05	ノバルティスアーゲー	抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
SG189174A1 (en)	2010-10-11	2013-05-31	Biogen Idec Internat Neuroscience Gmbh	Human anti-tau antibodies
AR083533A1 (es)	2010-10-22	2013-03-06	Boehringer Ingelheim Vetmed	Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
PL2635607T3 (pl)	2010-11-05	2020-05-18	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
AR083847A1 (es)	2010-11-15	2013-03-27	Novartis Ag	Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
TWI655210B (zh)	2010-12-08	2019-04-01	艾伯維史坦森特瑞斯有限責任公司	新穎調節劑及其使用方法
JP6067575B2 (ja)	2010-12-17	2017-01-25	ニューリミューンホールディングエイジー	ヒト抗ｓｏｄ１抗体
WO2012090073A2 (en)	2010-12-30	2012-07-05	The Netherlands Cancer Institute	Methods and compositions for predicting chemotherapy sensitivity
EP3763740A1 (de)	2011-01-26	2021-01-13	Celldex Therapeutics, Inc.	Anti-kit-antikörper und verwendungen davon
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
TWI719112B (zh)	2011-03-16	2021-02-21	賽諾菲公司	雙重ｖ區類抗體蛋白質之用途
AU2012240246A1 (en)	2011-04-04	2013-05-09	Netherlands Cancer Institute	Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
US20140296248A1 (en)	2011-04-04	2014-10-02	Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis	Methods and compositions for predicting resistance to anticancer treatment
US9150644B2 (en)	2011-04-12	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9409987B2 (en)	2011-04-15	2016-08-09	Compugen Ltd	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2699598B1 (de)	2011-04-19	2019-03-06	Pfizer Inc	Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs
WO2012145577A1 (en)	2011-04-20	2012-10-26	Merial Limited	Adjuvanted rabies vaccine with improved viscosity profile
AP2013007180A0 (en)	2011-04-25	2013-10-31	Advanced Bioscience Lab Inc	Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
RS58087B1 (sr)	2011-05-13	2019-02-28	Ganymed Pharmaceuticals Gmbh	Antitela za lečenje kancera koji eksprimira klaudin 6
EP2714738B1 (de)	2011-05-24	2018-10-10	Zyngenia, Inc.	Multivalente und monovalente multispezifische komplexe und ihre verwendungen
EP2714077B1 (de)	2011-06-01	2018-02-28	Merial, Inc.	Nadellose verabreichung von prrsv-impfstoffen
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
RS57024B1 (sr)	2011-06-10	2018-05-31	Medimmune Ltd	Anti-pseudomonas psl vezujući molekuli i njihova upotreba
US20130209449A9 (en)	2011-06-13	2013-08-15	Abgenomics Cooperatief U.A.	Anti-psgl-1 antibodies and uses thereof
CN103796679B (zh)	2011-06-23	2016-10-19	比奥根国际神经科学公司	抗-α突触核蛋白结合分子
PL2726094T3 (pl)	2011-06-28	2017-06-30	Oxford Biotherapeutics Ltd	Cel terapeutyczny i diagnostyczny
CN103649121B (zh)	2011-06-28	2016-10-19	牛津生物疗法有限公司	针对adp-核糖基环化酶2的抗体
MX358726B (es)	2011-06-29	2018-09-03	Amgen Inc	Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
WO2013001517A1 (en)	2011-06-30	2013-01-03	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
DK2726099T3 (en)	2011-07-01	2018-11-05	Novartis Ag	Method of treating metabolic disorders
HRP20180858T1 (hr)	2011-07-11	2018-09-21	Glenmark Pharmaceuticals S.A.	Protutijela koja se vežu na ox40 i njihove uporabe
BR112014001287B1 (pt)	2011-07-20	2020-12-08	Centre National De La Recherche Scientifique	vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
LT2741740T (lt)	2011-08-12	2017-08-10	Merial, Inc.	Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas
US9556281B2 (en)	2011-08-15	2017-01-31	The University Of Chicago	Compositions and methods related to antibodies to staphylococcal protein A
AR088028A1 (es)	2011-08-15	2014-05-07	Boehringer Ingelheim Vetmed	Proteinas h5, de h5n1 para un uso medicinal
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
WO2013033092A2 (en)	2011-09-03	2013-03-07	Boehringer Ingelheim Vetmedica Gmbh	Streptococcus suis pilus antigens
JP6216317B2 (ja)	2011-09-09	2017-10-18	メディミューンリミテッド	抗Ｓｉｇｌｅｃ−１５抗体およびその使用
PT2760471T (pt)	2011-09-30	2017-03-22	Dana Farber Cancer Inst Inc	Péptidos terapêuticos
US9316645B2 (en)	2011-10-07	2016-04-19	Brown University	Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging
EP2773664A1 (de)	2011-11-01	2014-09-10	Bionomics, Inc.	Anti-gpr49-antikörper
EP2773373B1 (de)	2011-11-01	2018-08-22	Bionomics, Inc.	Verfahren zur blockierung eines krebsstammzellenwachstums
JP2014533247A (ja)	2011-11-01	2014-12-11	バイオノミクスインコーポレイテッド	抗体および癌を治療する方法
AU2012332593B2 (en)	2011-11-01	2016-11-17	Bionomics, Inc.	Anti-GPR49 antibodies
PL2773671T3 (pl)	2011-11-04	2022-01-24	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
HK1205522A1 (en)	2011-11-08	2015-12-18	辉瑞公司	Methods of treating inflammatory disorders using anti-m-csf antibodies
WO2013078118A1 (en)	2011-11-21	2013-05-30	Bristol-Myers Squibb Company	Methods for determining the susceptibility of a virus to an attachment inhibitor
WO2013093629A2 (en)	2011-12-20	2013-06-27	Netherlands Cancer Institute	Modular vaccines, methods and compositions related thereto
EP3539982B1 (de)	2011-12-23	2025-02-19	Pfizer Inc.	Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
SG2014008304A (en)	2012-02-01	2014-06-27	Compugen Ltd	C10rf32 antibodies, and uses thereof for treatment of cancer
CN108324943B (zh)	2012-02-10	2024-03-08	思进股份有限公司	Cd30+癌症的检测和治疗
RU2014138474A (ru)	2012-02-24	2016-04-10	СтемСентРкс, Инк.	Новые модуляторы и способы применения
WO2013138776A1 (en)	2012-03-16	2013-09-19	Merial Limited	Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
ES2711878T3 (es)	2012-03-20	2019-05-08	Merial Inc	Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
NZ702282A (en)	2012-04-26	2016-07-29	Univ Chicago	Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
ES2729729T3 (es)	2012-05-07	2019-11-05	Astellas Pharma Inc	Anticuerpos que se unen a PLAC1 y bloquean la interacción entre PLAC1 y FGF7
WO2013167153A1 (en)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Antibodies useful in cancer diagnosis
JP6351572B2 (ja)	2012-05-10	2018-07-04	ザイムワークス，インコーポレイテッド	Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
MX381731B (es)	2012-05-14	2025-03-13	Biogen Ma Inc	Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
WO2013174403A1 (en)	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en)	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3791896B1 (de)	2012-05-23	2024-01-10	Astellas Pharma Inc.	Kombinationstherapie mit antikörpern gegen claudin 18.2 zur behandlung von krebs
EP4119582A1 (de)	2012-05-23	2023-01-18	Astellas Pharma Inc.	Kombinationstherapie mit antikörpern gegen claudin 18.2 zur behandlung von krebs
SG11201408037SA (en)	2012-06-08	2015-01-29	Glenmark Pharmaceuticals Sa	Humanized anti-trka antibodies with amino acid substitutions
CN110628822A (zh)	2012-06-13	2019-12-31	梅里亚有限公司	重配btv和ahsv疫苗
EP2674495A1 (de)	2012-06-14	2013-12-18	Sanofi	CHO-Expressionssystem
UY34887A (es)	2012-07-02	2013-12-31	Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware	Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN104812775B (zh)	2012-07-25	2019-05-03	塞尔德克斯医疗公司	抗kit抗体及其用途
GB201213652D0 (en)	2012-08-01	2012-09-12	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
EP2711426B1 (de)	2012-09-24	2015-04-08	Lonza Biologics plc	Expressionsvektoren mit chimärem Cytomegalieviruspromotor und Verstärkersequenzen
CN104870014A (zh)	2012-10-09	2015-08-26	比奥根Ma公司	联合治疗及用于治疗脱髓鞘病症的用途
JP2015531244A (ja)	2012-10-15	2015-11-02	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	タンパク質を製造するための哺乳動物細胞培養方法
BR122020024124B1 (pt)	2012-11-13	2024-01-30	Biontech Ag	Agentes para tratamento de doenças cancerosas expressando claudina
CN105073776B (zh)	2012-11-13	2019-04-12	拜恩科技股份公司	用于治疗表达紧密连接蛋白的癌症疾病的制剂
WO2014075697A1 (en)	2012-11-13	2014-05-22	Biontech Ag	Agents for treatment of claudin expressing cancer diseases
KR102286389B1 (ko)	2012-11-20	2021-08-05	노파르티스 아게	폴리펩티드를 고 수율로 발현하는 최적화 발현 카세트
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
JP6396313B2 (ja)	2012-12-07	2018-09-26	ファイザー・インク	操作された単量体抗体断片
HRP20192013T1 (hr)	2012-12-17	2020-02-07	Trillium Therapeutics Inc.	Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama
AR093984A1 (es)	2012-12-21	2015-07-01	Merck Sharp & Dohme	Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
HRP20201422T1 (hr)	2012-12-21	2021-02-19	Biogen Ma Inc.	Ljudska anti-tau antitijela
CN104936980B (zh)	2012-12-31	2019-06-07	生物控股有限公司	用于治疗和预防多瘤病毒相关的疾病的重组人抗体
EA201591153A1 (ru)	2013-01-02	2016-01-29	Гленмарк Фармасьютикалс С.А.	Антитела, связывающиеся с tl1a, и их применение
MX371052B (es)	2013-02-08	2020-01-14	Novartis Ag	Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios.
US9534041B2 (en)	2013-02-12	2017-01-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that neutralize a norovirus
GB201302447D0 (en)	2013-02-12	2013-03-27	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
WO2014129895A1 (en)	2013-02-19	2014-08-28	Stichting Vu-Vumc	Means and method for increasing the sensitivity of cancers for radiotherapy
WO2014127785A1 (en)	2013-02-20	2014-08-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP2958945B1 (de)	2013-02-20	2022-10-19	Astellas Pharma Inc.	Kombinationstherapie mit antikörpern gegen claudin 18.2 zur behandlung von krebs
WO2014127825A1 (en)	2013-02-21	2014-08-28	Boehringer Ingelheim Vetmedica Gmbh	H5 proteins of h5n1 influenza virus for use as a medicament
MX2015010682A (es)	2013-02-22	2016-05-31	Stemcentrx Inc	Nuevos conjugados de anticuerpos y usos de los mismos.
EP2968514A1 (de)	2013-03-12	2016-01-20	Merial, Inc.	Mittels reverser genetik hergestellte impfstoffzusammensetzungen gegen schmallenberg-virus und verfahren zur verwendung davon
NZ629816A (en)	2013-03-15	2017-07-28	Dana Farber Cancer Inst Inc	Therapeutic peptides
US9944992B2 (en)	2013-03-15	2018-04-17	The University Of Chicago	Methods and compositions related to T-cell activity
EP2976360B1 (de)	2013-03-18	2019-11-27	Astellas Pharma Inc.	Therapie mit antikörpern gegen claudin 18.2 zur behandlung von krebs
WO2014146672A1 (en)	2013-03-18	2014-09-25	Ganymed Pharmaceuticals Ag	Therapy involving antibodies against claudin 18.2 for treatment of cancer
US20160084839A1 (en)	2013-04-02	2016-03-24	Marisa Dolled-Filhart	Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
EP3583950A1 (de)	2013-05-09	2019-12-25	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Single-domain-vhh-antikörper gegen norovirus gi.1 und gii.4 und deren verwendung
WO2014186364A2 (en)	2013-05-13	2014-11-20	Tufts University	Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
WO2014186878A1 (en)	2013-05-24	2014-11-27	Cashman Neil R	Cell senescence markers as diagnostic and therapeutic targets
SG10201708143QA (en)	2013-06-06	2017-11-29	Pf Medicament	Anti-c10orf54 antibodies and uses thereof
WO2014200349A1 (en)	2013-06-13	2014-12-18	Fast Forward Pharmaceutical B.V.	Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
CA2916694C (en)	2013-06-28	2023-01-17	Baylor Research Institute	Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
EP3738612A1 (de)	2013-07-31	2020-11-18	Biontech AG	Diagnose und therapie von krebs mit krebsstammzellen
WO2015014376A1 (en)	2013-07-31	2015-02-05	Biontech Ag	Diagnosis and therapy of cancer involving cancer stem cells
CN105452296B (zh)	2013-08-01	2020-09-25	戊瑞治疗有限公司	无岩藻糖基化抗fgfr2iiib抗体
CA2918300A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Methods of treating sporadic inclusion body myositis
WO2015053871A2 (en)	2013-08-26	2015-04-16	MabVax Therapeutics, Inc.	NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
CA2922529A1 (en)	2013-08-28	2015-03-05	Stemcentrx, Inc.	Novel sez6 modulators and methods of use
PE20160674A1 (es)	2013-08-28	2016-07-21	Stemcentrx Inc	Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
WO2015050959A1 (en)	2013-10-01	2015-04-09	Yale University	Anti-kit antibodies and methods of use thereof
PT3052192T (pt)	2013-10-02	2020-09-24	Medimmune Llc	Anticorpos neutralizantes anti-influenza a e suas utilizações
JP6240337B2 (ja)	2013-10-22	2017-11-29	バイロメッドカンパニーリミテッド	肝細胞増殖因子の２つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物
EP2868328A1 (de)	2013-10-31	2015-05-06	Universitätsklinikum Regensburg	Blockade Il-3 bei systemischem Lupus erythematosus und multipler Sklerose
CN106029694A (zh)	2013-12-06	2016-10-12	达纳-法伯癌症研究院公司	治疗性肽
EP4124624A3 (de)	2013-12-20	2023-05-03	Intervet International B.V.	Antikörper gegen hunde-pd-1
CN104805107B (zh) *	2014-01-26	2018-03-23	中国人民解放军军事医学科学院生物工程研究所	一种基于gs筛选系统的动物细胞高效表达载体及应用
EP2910645A1 (de)	2014-02-25	2015-08-26	STRATIFYER Molecular Pathology GmbH	Verfahren und Zusammensetzungen zur Vorhersage der therapeutischen Wirksamkeit von Krebsbehandlungen und Krebsprognose bei Antikörperbehandlung
CN113491766A (zh)	2014-03-14	2021-10-12	达纳－法伯癌症研究所公司	恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
CN112316129B (zh)	2014-04-03	2025-01-28	勃林格殷格翰动物保健美国有限公司	猪流行性腹泻病毒疫苗
AU2015240599B2 (en)	2014-04-04	2020-11-19	Bionomics, Inc.	Humanized antibodies that bind LGR5
JP2017518737A (ja)	2014-04-21	2017-07-13	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
EP3137114B8 (de)	2014-04-30	2021-08-04	Pfizer Inc.	Anti-ptk7-antikörper-arzneimittelkonjugate
US10392438B2 (en)	2014-05-16	2019-08-27	Pfizer Inc.	Bispecific antibodies
EP3142700B1 (de)	2014-05-16	2021-03-03	Medimmune, LLC	Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
DK3148579T3 (da)	2014-05-28	2021-03-08	Agenus Inc	Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
KR102226248B1 (ko)	2014-06-04	2021-03-12	바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드	강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
AU2015271709B2 (en)	2014-06-06	2020-11-26	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
US20170291939A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Antibodies specific for il-17a fused to hyaluronan binding peptide tags
CA2954780A1 (en)	2014-07-15	2016-01-21	Medimmune, Llc	Neutralizing anti-influenza b antibodies and uses thereof
AU2015289386A1 (en) *	2014-07-18	2017-03-09	Celltheon Corporation	Methods and compositions for expression of polypeptides in a cell
CN107074937B (zh)	2014-07-29	2021-07-27	神经免疫控股公司	人源抗亨廷顿蛋白(htt)抗体及其用途
CR20170060A (es)	2014-08-19	2017-04-18	Merck Sharp & Dohme	Anticuerpos anti tigit
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
ES2748295T3 (es)	2014-09-16	2020-03-16	Symphogen As	Anticuerpos anti-MET y composiciones
NZ729808A (en)	2014-09-30	2022-02-25	Neurimmune Holding Ag	Human-derived anti-dipeptide repeats (dprs) antibody
SG10201902924RA (en)	2014-10-03	2019-05-30	Massachusetts Inst Technology	Antibodies that bind ebola glycoprotein and uses thereof
ES2769877T3 (es)	2014-10-23	2020-06-29	Sanofi Sa	Marcador de selección novedoso para la transfección celular y la producción de proteínas
EP3015475A1 (de)	2014-10-31	2016-05-04	Novartis AG	Säugetierzellen zur Expression von Cytomegalovirus-Antigenen
WO2016073410A1 (en)	2014-11-03	2016-05-12	Merial, Inc.	Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
TWI711630B (zh)	2014-11-21	2020-12-01	美商必治妥美雅史谷比公司	抗ｃｄ７３抗體及其用途
WO2016090170A1 (en)	2014-12-05	2016-06-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	A potent anti-influenza a neuraminidase subtype n1 antibody
WO2016094837A2 (en)	2014-12-11	2016-06-16	Igenica Biotherapeutics, Inc.	Anti-c10orf54 antibodies and uses thereof
CN107278206B (zh)	2014-12-19	2021-04-02	雷根尼桑斯公司	结合人c6的抗体及其用途
EP3789039A1 (de)	2014-12-22	2021-03-10	The Rockefeller University	Anti-mertk-antikörper und verwendungen davon
MY187045A (en)	2014-12-23	2021-08-27	Bristol Myers Squibb Co	Antibodies to tigit
SI3240801T1 (sl)	2014-12-31	2021-04-30	Checkmate Pharmaceuticals, Inc.	Kombinirana imunoterapija tumorja
JP2018504400A (ja)	2015-01-08	2018-02-15	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
US10590457B2 (en)	2015-02-11	2020-03-17	Bristol Myers-Squibb Company	Compositions for cell culture and methods of using the same
EP3259597B2 (de)	2015-02-19	2026-04-15	Compugen Ltd.	Pvrig-polypeptide und verfahren zur behandlung
EP3268037B1 (de)	2015-03-09	2022-08-31	Celldex Therapeutics, Inc.	Cd27 agonists
CN108064236B (zh)	2015-03-31	2021-12-10	免疫医疗有限公司	新颖的il33形式、il33的突变形式、抗体、测定及其使用方法
JP6938383B2 (ja)	2015-04-02	2021-09-22	インターベットインターナショナルベー．フェー．	イヌインターロイキン４受容体アルファに対する抗体
WO2016164308A1 (en)	2015-04-06	2016-10-13	Subdomain, Llc	De novo binding domain containing polypeptides and uses thereof
WO2016165765A1 (en)	2015-04-15	2016-10-20	Ganymed Pharmaceuticals Ag	Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016165762A1 (en)	2015-04-15	2016-10-20	Ganymed Pharmaceuticals Ag	Drug conjugates comprising antibodies against claudin 18.2
AU2016256911B2 (en)	2015-05-07	2022-03-31	Agenus Inc.	Anti-OX40 antibodies and methods of use thereof
CA2986765A1 (en)	2015-05-29	2016-12-08	Agenus Inc.	Anti-ctla-4 antibodies and methods of use thereof
EA035412B1 (ru)	2015-05-29	2020-06-10	Бристол-Майерс Сквибб Компани	Антитела к ox40 и их применение
EP3960761A1 (de)	2015-06-01	2022-03-02	MedImmune, LLC	Neutralisierende anti-antiinfluenza-bindungsmoleküle und verwendungen davon
ES3050936T3 (en)	2015-06-23	2025-12-23	Boehringer Ingelheim Vetmedica Gmbh	Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
UY36751A (es)	2015-06-26	2017-01-31	Novartis Ag	Anticuerpos de factor xi y métodos de uso
US10479838B2 (en)	2015-06-29	2019-11-19	Bristol-Myers Squibb Company	Antibodies to CD40 with enhanced agonist activity
CA2991980A1 (en)	2015-07-13	2017-01-19	Compugen Ltd.	Hide1 compositions and methods
EP3337822A1 (de)	2015-08-19	2018-06-27	Rutgers, The State University of New Jersey	Neuartige verfahren zur erzeugung von antikörpern
AU2016308630B2 (en)	2015-08-20	2019-09-19	Boehringer Ingelheim Animal Health USA Inc.	FCV recombinant vaccines and uses thereof
US9920302B2 (en)	2015-08-31	2018-03-20	Boehringer Ingelheim Vetmedica Gmbh	Pestivirus vaccines for congenital tremors
EP3344656A1 (de)	2015-09-01	2018-07-11	Agenus Inc.	Anti-pd-1-antikörper und verfahren zur verwendung davon
KR20180042449A (ko)	2015-09-15	2018-04-25	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	T 세포 수용체(tcr) 결합 항체 및 이의 용도
CA2996613A1 (en)	2015-09-16	2017-03-23	Boehringer Ingelheim Vetmedica, Inc.	Salmonella choleraesuis-salmonella typhimurium vaccines
RU2638457C2 (ru)	2015-09-28	2017-12-13	Общество С Ограниченной Ответственностью "Онкомакс"	Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
ES2974666T3 (es)	2015-09-29	2024-07-01	Boehringer Ingelheim Animal Health Usa Inc	Vacunas de partículas similares a virus (VLP) del parvovirus canino (CPV) y usos de las mismas
AU2016333517B2 (en)	2015-10-02	2023-09-07	Les Laboratoires Servier	Anti-PD-1 antibodies and compositions
WO2017066714A1 (en)	2015-10-16	2017-04-20	Compugen Ltd.	Anti-vsig1 antibodies and drug conjugates
JO3555B1 (ar)	2015-10-29	2020-07-05	Merck Sharp & Dohme	جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
WO2017083224A1 (en)	2015-11-09	2017-05-18	Bristol-Myers Squibb Company	Methods to manipulate quality attributes of polypeptides produced in cho cells
CA3132021C (en)	2015-11-18	2024-03-12	Merck Sharp & Dohme Corp.	Pd1 and/or lag3 binders
CA3003777A1 (en)	2015-11-18	2017-05-26	Merck Sharp & Dohme Corp.	Pd1/ctla4 binders
MY189590A (en)	2015-11-18	2022-02-18	Merck Sharp & Dohme	Ctla4 binders
CA3005855A1 (en)	2015-11-19	2017-05-26	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
CN107406504B (zh)	2015-11-19	2021-04-30	蔡则玲	Ctla-4抗体及其用途
RU2745707C2 (ru)	2015-11-23	2021-03-30	Файв Прайм Терапьютикс, Инк.	Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
KR102630475B1 (ko)	2015-11-30	2024-01-26	브리스톨-마이어스 스큅 컴퍼니	항 인간 ip-10 항체 및 이의 용도
US20190169262A1 (en)	2015-12-04	2019-06-06	Board Of Regents, The University Of Texas System	Slc45a2 peptides for immunotherapy
JP7000322B2 (ja)	2015-12-16	2022-02-04	メルク・シャープ・アンド・ドーム・コーポレーション	抗ｌａｇ３抗体および抗原結合性フラグメント
CA3005696A1 (en)	2015-12-18	2017-06-22	Intervet International B.V.	Caninized human antibodies to human and canine il-4r alpha
TWI760322B (zh)	2016-01-29	2022-04-11	美商百靈佳殷格翰動物保健美國有限公司	重組腺病毒載體裝載之fmdv疫苗及其用途
KR20180107151A (ko)	2016-02-17	2018-10-01	노파르티스 아게	Tgf베타 2 항체
CA3016187A1 (en)	2016-03-04	2017-09-08	Bristol-Myers Squibb Company	Combination therapy with anti-cd73 antibodies
KR20180114223A (ko)	2016-03-04	2018-10-17	더 락커펠러 유니버시티	증진된 효능제 활성을 갖는 cd40에 대한 항체
JP6979976B2 (ja)	2016-03-10	2021-12-15	ヴィエラバイオ，インコーポレーテッド	Ｉｌｔ７結合分子及びその使用方法
KR20180138205A (ko)	2016-03-22	2018-12-28	바이오노믹스 리미티드	항-lgr5 단클론성 항체의 투여
RS62736B1 (sr)	2016-04-12	2022-01-31	Symphogen As	Anti-tim-3 antitela i kompozicije
JP7038064B2 (ja)	2016-04-18	2022-03-17	セルデックスセラピューティクスインコーポレイテッド	ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
CA3019588A1 (en)	2016-04-20	2017-10-26	Merck Sharp & Dohme Corp.	Cmv neutralizing antigen binding proteins
US10968279B2 (en)	2016-05-09	2021-04-06	Bristol-Myers Squibb Company	TL1A antibodies and uses thereof
TW201802121A (zh)	2016-05-25	2018-01-16	諾華公司	抗因子XI/XIa抗體之逆轉結合劑及其用途
MX389710B (es)	2016-05-27	2025-03-20	Agenus Inc	Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
US10851159B2 (en)	2016-06-02	2020-12-01	Bloom Diagnostics Ag	Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
EP3481864A1 (de)	2016-07-08	2019-05-15	Staten Biotechnology B.V.	Anti-apoc3-antikörper und verfahren zur verwendung davon
US20200031924A1 (en)	2016-07-13	2020-01-30	Biogen Ma Inc.	Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders
JP2018035137A (ja)	2016-07-13	2018-03-08	マブイミューンダイアグノスティックスエイジーＭａｂｉｍｍｕｎｅＤｉａｇｎｏｓｔｉｃｓＡｇ	新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
SG11201900026TA (en)	2016-07-14	2019-01-30	Bristol Myers Squibb Co	Antibodies against tim3 and uses thereof
NL2017270B1 (en)	2016-08-02	2018-02-09	Aduro Biotech Holdings Europe B V	New anti-hCTLA-4 antibodies
SG11201901077RA (en)	2016-08-17	2019-03-28	Compugen Ltd	Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
JP6949106B2 (ja)	2016-08-23	2021-10-13	メディミューンリミテッド	抗ｖｅｇｆ−ａ抗体ならびにそれらの使用
WO2018035710A1 (en)	2016-08-23	2018-03-01	Akeso Biopharma, Inc.	Anti-ctla4 antibodies
EP3504237A1 (de)	2016-08-23	2019-07-03	Medimmune Limited	Anti-vegf-a- und anti-ang2-antikörper und verwendungen davon
AR109538A1 (es)	2016-09-20	2018-12-19	Boehringer Ingelheim Vetmedica Gmbh	Vacuna contra la gripe porcina
AU2017332677B2 (en)	2016-09-20	2024-01-11	Boehringer Ingelheim Vetmedica Gmbh	Canine adenovirus vectors
CN109715204B (zh)	2016-09-20	2023-08-22	勃林格殷格翰动物保健有限公司	新的ehv插入位点orf70
DK3516064T3 (da)	2016-09-20	2025-07-14	Boehringer Ingelheim Vetmedica Gmbh	Nye promotorer
WO2018054484A1 (en)	2016-09-23	2018-03-29	Biontech Ag	Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
JOP20190055A1 (ar)	2016-09-26	2019-03-24	Merck Sharp & Dohme	أجسام مضادة ضد cd27
KR102576042B1 (ko)	2016-10-11	2023-09-07	아게누스 인코포레이티드	항-lag-3 항체 및 이의 사용 방법
CA3040189A1 (en)	2016-10-13	2018-04-19	Massachusetts Institute Of Technology	Antibodies that bind zika virus envelope protein and uses thereof
US11390676B2 (en)	2016-10-13	2022-07-19	Symphogen A/S	Anti-LAG-3 antibodies and compositions
EA201991065A1 (ru)	2016-11-03	2019-11-29		Вакцина против свиного парвовируса
AU2017353380B2 (en)	2016-11-03	2024-08-22	Boehringer Ingelheim Vetmedica Gmbh	Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
KR102431830B1 (ko)	2016-11-07	2022-08-16	주식회사 뉴라클사이언스	서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
US11359018B2 (en)	2016-11-18	2022-06-14	Symphogen A/S	Anti-PD-1 antibodies and compositions
US10759855B2 (en)	2016-12-02	2020-09-01	Rigel Pharmaceuticals, Inc.	Antigen binding molecules to TIGIT
FI3551660T3 (fi)	2016-12-07	2023-12-11	Agenus Inc	Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
BR112019012667A2 (pt)	2016-12-23	2020-02-11	Novartis Ag	Anticorpos do fator xi e métodos de uso
US10603358B2 (en)	2017-01-10	2020-03-31	Nodus Therapeutics	Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
US10350266B2 (en)	2017-01-10	2019-07-16	Nodus Therapeutics, Inc.	Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3573655A2 (de)	2017-01-30	2019-12-04	Boehringer Ingelheim Animal Health USA Inc.	Impfstoffe gegen porzines coronavirus
EA201991720A1 (ru)	2017-02-17	2020-01-20	Бристол-Маерс Сквибб Компани	Антитела к альфа-синуклеину и их применения
SI3600415T1 (sl)	2017-03-24	2026-01-30	Novartis Ag	Protitelo proti aktivinskemu receptorju tipa ii za uporabo pri zdravljenju srčnega popuščanja
KR102737715B1 (ko)	2017-04-05	2024-12-03	르 라보레또레 쎄르비에르	Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
JP7297672B2 (ja)	2017-04-13	2023-06-26	アジェナスインコーポレイテッド	抗ｃｄ１３７抗体およびその使用方法
WO2018190719A2 (en)	2017-04-13	2018-10-18	Aduro Biotech Holdings, Europe B.V.	Anti-sirp alpha antibodies
RU2665790C1 (ru)	2017-04-17	2018-09-04	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело к pd-l1
CA3059133A1 (en)	2017-04-21	2018-10-25	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
US11203629B2 (en)	2017-04-22	2021-12-21	Immunomic Therapeutics, Inc.	LAMP constructs
EP3615070A1 (de)	2017-04-26	2020-03-04	Bristol-Myers Squibb Company	Verfahren zur antikörperproduktion mit minimaler disulfidbindungsreduzierung
RS64576B1 (sr)	2017-05-01	2023-10-31	Agenus Inc	Anti-tigit antitela i postupci njihove primene
CA3061950A1 (en)	2017-05-02	2018-11-08	Immunomic Therapeutics, Inc.	Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
IL270244B2 (en)	2017-05-05	2025-01-01	Vaccinex Inc	Antibody against human semaphorin 4D
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
LT3624837T (lt)	2017-05-16	2025-10-10		Anti-fgfr2 antikūnai derinyje su chemoterapijos agentais vėžio gydymui
JP7076059B2 (ja)	2017-06-27	2022-05-27	ニューラクルサイエンスカンパニーリミテッド	抗ｆａｍ１９ａ５抗体及びその用途
EP3645564A1 (de)	2017-06-28	2020-05-06	Novartis AG	Verfahren zur prävention und behandlung von harninkontinenz
CA3068672A1 (en)	2017-06-28	2019-01-03	The Rockefeller University	Anti-mertk agonistic antibody-drug conjugates and uses thereof
GB201710838D0 (en)	2017-07-05	2017-08-16	Ucl Business Plc	Bispecific antibodies
GB201710973D0 (en)	2017-07-07	2017-08-23	Avacta Life Sciences Ltd	Scaffold proteins
EP3651797A1 (de)	2017-07-12	2020-05-20	Boehringer Ingelheim Animal Health USA Inc.	Immunogene senecavirus-a-zusammensetzungen und verfahren dafür
AU2018300189B2 (en)	2017-07-14	2025-05-15	Pfizer, Inc.	Antibodies to MAdCAM
CN111511762B (zh)	2017-08-21	2025-05-06	天演药业公司	抗cd137分子及其用途
TWI817952B (zh)	2017-08-25	2023-10-11	美商戊瑞治療有限公司	Ｂ７－ｈ４抗體及其使用方法
WO2019048040A1 (en)	2017-09-06	2019-03-14	Ganymed Pharmaceuticals Gmbh	ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
KR20200057742A (ko)	2017-09-23	2020-05-26	베링거잉겔하임베트메디카게엠베하	파라믹소바이러스과 발현 시스템
EA039662B1 (ru)	2017-10-03	2022-02-24	Закрытое Акционерное Общество "Биокад"	Антитела, специфичные к cd47 и pd-l1
RU2698048C2 (ru)	2017-10-03	2019-08-21	Закрытое Акционерное Общество "Биокад"	МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
CA3081336A1 (en)	2017-10-12	2019-04-18	Gregory LIZEE	T cell receptors for immunotherapy
CN111630069B (zh)	2017-10-13	2024-05-31	勃林格殷格翰国际有限公司	针对Thomsen-nouvelle(Tn)抗原的人抗体
CA3080103A1 (en)	2017-10-31	2019-05-09	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
AU2018361743A1 (en)	2017-11-03	2020-04-09	Novartis Ag	Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
WO2019092027A1 (en)	2017-11-09	2019-05-16	Boehringer Ingelheim Vetmedica Gmbh	Sapelovirus immunogenic compositions and uses thereof
WO2019099440A1 (en)	2017-11-14	2019-05-23	Arcellx, Inc.	Multifunctional immune cell therapies
BR112020009136A2 (pt)	2017-11-14	2020-10-13	Arcellx, Inc.	polipeptídeos que contêm domínio d e usos dos mesmos
JP7284759B2 (ja)	2017-12-27	2023-05-31	ブリストル－マイヤーズスクイブカンパニー	抗ｃｄ４０抗体およびその使用
JP7358361B2 (ja)	2018-01-12	2023-10-10	ブリストル－マイヤーズスクイブカンパニー	Ｔｉｍ３に対する抗体およびその使用
PT110526B (pt)	2018-01-26	2021-02-04	Univ Nova De Lisboa	Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
WO2019148412A1 (en)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anti-pd-1/lag3 bispecific antibodies
WO2019148445A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Anti-ctla4 antibodies and methods of making and using the same
KR20200119311A (ko)	2018-02-12	2020-10-19	트러스티즈 오브 터프츠 칼리지	인플라마좀 활성화를 억제하기 위한 cd59
EP3752194A4 (de)	2018-02-13	2022-03-16	Checkmate Pharmaceuticals, Inc.	Zusammensetzungen und verfahren für die tumorimmuntherapie
BR112020016986A2 (pt)	2018-02-21	2021-03-02	Five Prime Therapeutics, Inc.	formulações de anticorpo contra b7-h4
CN111712575B (zh)	2018-02-23	2024-07-19	勃林格殷格翰动物保健有限公司	表达外源猫副粘病毒基因的重组病毒载体系统及由其制备的疫苗
CA3091801A1 (en)	2018-03-02	2019-09-06	Five Prime Therapeutics, Inc.	B7-h4 antibodies and methods of use thereof
NL2020520B1 (en)	2018-03-02	2019-09-12	Labo Bio Medical Invest B V	Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
JP7245260B2 (ja)	2018-03-19	2023-03-23	ベーリンガーインゲルハイムフェトメディカゲーエムベーハー	Ｅｈｖ挿入部位ｕｌ４３
AR115002A1 (es)	2018-03-19	2020-11-18	Boehringer Ingelheim Vetmedica Gmbh	Ehv con ul18 y/o ul8 inactivados
TWI841554B (zh)	2018-03-21	2024-05-11	丹麥商珍美寶股份有限公司	以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CA3093407A1 (en)	2018-03-23	2019-09-26	Bristol-Myers Squibb Company	Antibodies against mica and/or micb and uses thereof
KR20260008832A (ko)	2018-03-26	2026-01-16	베링거 인겔하임 애니멀 헬스 유에스에이 인크.	면역원성 조성물의 제조방법
SG11202009647VA (en)	2018-04-09	2020-10-29	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
US10654944B2 (en)	2018-04-10	2020-05-19	Y-Biologics Inc.	Cell engaging binding molecules
EP3773739A1 (de)	2018-04-12	2021-02-17	MediaPharma S.r.l.	Lgals3bp-antikörper-wirkstoff-konjugat und seine verwendung bei der behandlung von krebs
US11780927B2 (en)	2018-04-13	2023-10-10	Novartis Ag	Anti-CD40 antibodies for use in prevention of graft rejection
WO2019204462A2 (en)	2018-04-17	2019-10-24	Celldex Therapeutics, Inc.	Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
KR20210018807A (ko)	2018-04-27	2021-02-18	바이오젠 엠에이 인코포레이티드	인간-유래 항-(폴리-ga) 디펩타이드 반복 (dpr) 항체
CA3099547A1 (en)	2018-05-07	2019-11-14	Reshma Abdulla RANGWALA	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2019217457A1 (en)	2018-05-07	2019-11-14	Genmab A/S	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
KR20240056644A (ko)	2018-05-10	2024-04-30	주식회사 뉴라클사이언스	서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
CA3103040A1 (en)	2018-05-11	2019-11-14	Wuxi Biologics (Shanghai) Co., Ltd.	Fully human antibodies against ox40, method for preparing same, and use thereof
BR112020024223A2 (pt)	2018-05-30	2021-03-16	Abbvie Stemcentrx Llc	Conjugados anticorpo fármaco anti-sez6 e métodos de uso
JP7457661B2 (ja)	2018-06-04	2024-03-28	バイオジェン・エムエイ・インコーポレイテッド	低減したエフェクター機能を有する抗ｖｌａ－４抗体
US12006357B2 (en)	2018-06-26	2024-06-11	Mor Research Applications Ltd.	Transthyretin antibodies and uses thereof
CN119930818A (zh)	2018-06-29	2025-05-06	爱必泰生物有限公司	抗l1cam抗体及其用途
WO2020037215A1 (en)	2018-08-17	2020-02-20	Icahn School Of Medicine At Mount Sinai	Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
RU2706298C1 (ru)	2018-09-14	2019-11-15	Закрытое Акционерное Общество "Биокад"	НУКЛЕАЗА PaCas9
TW202026010A (zh)	2018-09-20	2020-07-16	德商百靈佳殷格翰維美迪加股份有限公司	抗豬流行性下痢之鼻內載體疫苗
TW202027785A (zh)	2018-09-20	2020-08-01	德商百靈佳殷格翰維美迪加股份有限公司	經修飾之pedv棘蛋白
AU2019352017A1 (en)	2018-10-03	2021-05-06	Staten Biotechnology B.V.	Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
TWI844571B (zh)	2018-10-30	2024-06-11	丹麥商珍美寶股份有限公司	使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
RU2724469C2 (ru)	2018-10-31	2020-06-23	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело, которое специфически связывается с cd20
BR112021009111A2 (pt)	2018-11-16	2021-08-24	Bristol-Myers Squibb Company	Anticorpos anti-nkg2a e usos dos mesmos
JP2022513626A (ja)	2018-11-26	2022-02-09	ノバルティスアーゲー	Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
TW202039554A (zh)	2018-12-19	2020-11-01	瑞士商諾華公司	抗ＴＮＦ－α抗體
CN113195533B (zh)	2019-01-02	2024-04-26	纽洛可科学有限公司	抗序列相似家族19成员a5的抗体及其使用方法
CA3125886A1 (en)	2019-01-11	2020-07-16	Novartis Ag	Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
CN109762067B (zh)	2019-01-17	2020-02-28	北京天广实生物技术股份有限公司	结合人Claudin 18.2的抗体及其用途
EP3914622A1 (de)	2019-01-22	2021-12-01	Bristol-Myers Squibb Company	Antikörper gegen il-7r-alpha-untereinheit und deren verwendungen
WO2020163225A1 (en)	2019-02-05	2020-08-13	Seattle Genetics, Inc.	Anti-cd228 antibodies and antibody-drug conjugates
JP7588080B2 (ja)	2019-02-13	2024-11-21	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	抗末梢リンパ節アドレッシン抗体およびその使用
ES2978570T3 (es)	2019-02-26	2024-09-16	Inspirna Inc	Anticuerpos anti-MERTK de alta afinidad y sus usos
US10570210B1 (en)	2019-03-04	2020-02-25	Beijing Mabworks Biotech Co.Ltd	Antibodies binding CD40 and uses thereof
WO2020188021A1 (en)	2019-03-19	2020-09-24	Sanofi	Novel selection marker-comprising cell line and uses thereof for protein production
RU2734432C1 (ru)	2019-04-23	2020-10-16	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело, которое специфически связывается с GITR
AU2020267953A1 (en)	2019-05-08	2021-11-18	Novartis Ag	Anti-CD40 antibodies for use in treatment of T1DM and insulitis
AU2020283906A1 (en)	2019-05-31	2022-01-20	Trustees Of Tufts College	Anti-ADAM8 antibodies and uses of the same
CN113966345B (zh)	2019-06-12	2024-12-13	诺华股份有限公司	利钠肽受体1抗体及使用方法
BR112021026410A2 (pt)	2019-07-01	2022-02-08	Tonix Pharma Ltd	Anticorpos anti-cd154 e usos dos mesmos
EP3999539A1 (de)	2019-07-15	2022-05-25	Intervet International B.V.	Caninisierte antikörper gegen humanes und canines ctla-4
CA3145345A1 (en)	2019-07-15	2021-01-21	Intervet International B.V.	Caninized antibodies against canine ctla-4
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
MX2022001882A (es)	2019-08-12	2022-05-30	Aptevo Res & Development Llc	Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
KR20220053007A (ko)	2019-08-30	2022-04-28	아게누스 인코포레이티드	항-cd96 항체 및 이의 사용 방법
CA3148890A1 (en)	2019-09-11	2021-03-18	Novartis Ag	A method for preventing human virus associated disorders in patients
RU2753282C2 (ru)	2019-09-19	2021-08-12	Закрытое Акционерное Общество "Биокад"	ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
GB201913697D0 (en)	2019-09-23	2019-11-06	King S College London	DAP10/DAP12 fusion polypeptides
WO2021058091A1 (en)	2019-09-24	2021-04-01	Biontech Rna Pharmaceuticals Gmbh	Treatment involving therapeutic antibody and interleukin-2 (il2)
KR20220075351A (ko)	2019-10-04	2022-06-08	씨젠 인크.	항-pd-l1 항체 및 항체-약물 접합체
TW202128775A (zh)	2019-10-16	2021-08-01	英商阿法克塔生命科學有限公司	PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
JP2022551732A (ja)	2019-10-18	2022-12-13	イミュノミックセラピューティックス，インコーポレイテッド	がん抗原を含む改良ｌａｍｐ構築物
WO2021079002A2 (en)	2019-10-24	2021-04-29	Novago Therapeutics Ag	Novel anti-nogo-a antibodies
WO2021091815A1 (en)	2019-11-04	2021-05-14	Seagen Inc.	Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
JP2023500888A (ja)	2019-11-07	2023-01-11	ジェンマブエー／エス	抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
TW202131954A (zh)	2019-11-07	2021-09-01	丹麥商珍美寶股份有限公司	利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
CN114829396A (zh)	2019-12-20	2022-07-29	英特维特国际股份有限公司	用于治疗特应性皮炎的双特异性犬源化抗体和双特异性结合伴体
MX2022007677A (es)	2019-12-20	2022-07-19	Intervet Int Bv	Anticuerpos para receptor alfa de interleucina-4 canino.
TWI877278B (zh)	2019-12-30	2025-03-21	美商思進公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021136308A1 (en)	2020-01-03	2021-07-08	Biosion Inc.	Antibodies binding bcma and uses thereof
US11858962B2 (en)	2020-02-06	2024-01-02	Boehringer Ingelheim Vetmedica Gmbh	Polypeptides useful for detecting anti-rhabdovirus antibodies
JP2023513834A (ja)	2020-02-18	2023-04-03	アレクトルエルエルシー	Ｐｉｌｒａ抗体及びその使用方法
BR112022017174A2 (pt)	2020-02-27	2022-10-18	Chia Tai Tianqing Pharmaceutical Group Co Ltd	Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
JP2023516028A (ja)	2020-02-28	2023-04-17	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	多重特異性抗体を介したトランスフォーミング増殖因子ベータスーパーファミリーシグナル伝達の選択的調節
GB202003277D0 (en)	2020-03-06	2020-04-22	King S College London	Therapeutic agents
MX2022011892A (es)	2020-03-26	2022-10-18	Univ Vanderbilt	Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
IL297806A (en)	2020-04-30	2022-12-01	Sairopa B V	Anti-cd103 antibodies
EP3909601A1 (de)	2020-05-11	2021-11-17	LeukoCom GmbH	Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
AU2021271960A1 (en)	2020-05-12	2023-02-02	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	ST2 antigen binding protein
WO2021228178A1 (en)	2020-05-13	2021-11-18	Adagene Ag	Compositions and methods for treating cancer
WO2021231732A1 (en)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Antibodies to garp
CA3182150A1 (en)	2020-05-17	2021-11-25	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of selecting and using the same
GB202007655D0 (en)	2020-05-22	2020-07-08	King S College London	Chimeric nkg2d protein
RU2742837C1 (ru)	2020-06-02	2021-02-11	Общество С Ограниченной Ответственностью "Анабион"	Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок SMN1, и ее применение
WO2021245184A1 (en)	2020-06-02	2021-12-09	Neurimmune Ag	HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
GB202101299D0 (en)	2020-06-09	2021-03-17	Avacta Life Sciences Ltd	Diagnostic polypetides and methods
EP4171652A1 (de)	2020-06-29	2023-05-03	Genmab A/S	Antikörper-wirkstoff-konjugate gegen den gewebefaktor und deren verwendung bei der behandlung von krebs
EP4175982A1 (de)	2020-06-30	2023-05-10	Fondazione Toscana Life Sciences	Neutralisierende antikörper gegen sars-coronavirus-2
IT202000015754A1 (it)	2020-06-30	2021-12-30	Fond Toscana Life Sciences	Antibodies to coronavirus
BR112023000603A2 (pt)	2020-07-20	2023-01-31	Astrazeneca Uk Ltd	Proteínas sars-cov-2, anticorpos anti-sars-cov-2 e métodos de uso dos mesmos
CA3189336A1 (en)	2020-07-24	2022-01-27	Amgen Inc.	Immunogens derived from sars-cov2 spike protein
US20230295330A1 (en)	2020-08-04	2023-09-21	Seagen Inc.	Anti-cd228 antibodies and antibody-drug conjugates
HUE070287T2 (hu)	2020-08-18	2025-05-28	Cephalon Llc	Anti-PAR-2 ellenanyagok és eljárások alkalmazásukra
IL300917A (en)	2020-09-04	2023-04-01	Univ Rutgers	Sars-cov-2 vaccines and antibodies
TWI912369B (zh)	2020-09-21	2026-01-21	法商賽諾菲公司	用於生產治療蛋白之高生產重組中國倉鼠卵巢細胞株之世代
WO2022076977A1 (en)	2020-10-05	2022-04-14	Boehringer Ingelheim Animal Health USA Inc.	Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
JP2023544396A (ja)	2020-10-05	2023-10-23	ベーリンガーインゲルハイムフェトメディカゲーエムベーハー	ロタウイルスに対するワクチン接種のために有用な融合タンパク質
KR20230113286A (ko)	2020-10-13	2023-07-28	아비타이드 엘엘씨	Aav8 친화성 제제
WO2022081779A1 (en)	2020-10-13	2022-04-21	Avitide LLC	Affinity ligand libraries of three-helix bundle proteins and uses thereof
US20240002518A1 (en)	2020-10-15	2024-01-04	Intervet Inc.	Caninized rat antibodies to canine interleukin-31 receptor alpha
JP2023547499A (ja)	2020-11-06	2023-11-10	ノバルティスアーゲー	抗体Ｆｃ変異体
CA3197951A1 (en)	2020-11-11	2022-05-19	Ugur Sahin	Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
US20240024320A1 (en)	2020-11-17	2024-01-25	Seagen Inc.	Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
EP4255574A1 (de)	2020-12-01	2023-10-11	Aptevo Research and Development LLC	Heterodimere psma- und cd3-bindende bispezifische antikörper
MX2023006777A (es)	2020-12-11	2023-08-17	Univ North Carolina Chapel Hill	Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
US20240052042A1 (en)	2020-12-14	2024-02-15	Novartis Ag	Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
WO2022144406A1 (en)	2020-12-29	2022-07-07	Neurimmune Ag	Human anti-tau antibodies
JP2024504912A (ja)	2020-12-30	2024-02-02	イミュノミックセラピューティックス，インコーポレイテッド	抗ｈｖｅｍ抗体
CN114685669A (zh)	2020-12-30	2022-07-01	和铂医药(苏州)有限公司	结合trop2的抗体及其用途
CN117241866A (zh)	2021-02-19	2023-12-15	艾维泰有限责任公司	Aav2亲和剂
ES3065672T3 (en)	2021-03-23	2026-05-07	King S College London	Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
TW202304506A (zh)	2021-03-25	2023-02-01	日商安斯泰來製藥公司	涉及抗claudin 18.2抗體的組合治療以治療癌症
CN117425484A (zh)	2021-03-26	2024-01-19	阿奇利克斯股份有限公司	多功能免疫细胞疗法
EP4314077A1 (de)	2021-03-26	2024-02-07	BioNTech SE	Kombinationstherapie mit einem anti-ca19-9-antikörper und folfirinox bei der behandlung von krebs
EP4314068A1 (de)	2021-04-02	2024-02-07	The Regents Of The University Of California	Antikörper gegen gespaltenes cdcp1 und verwendungen davon
EP4320159A1 (de)	2021-04-09	2024-02-14	Celldex Therapeutics, Inc.	Antikörper gegen ilt4, bispezifische anti-ilt4/pd-l1-antikörper und verwendungen davon
WO2022234003A1 (en)	2021-05-07	2022-11-10	Avacta Life Sciences Limited	Cd33 binding polypeptides with stefin a protein
CA3218481A1 (en)	2021-06-14	2022-12-22	argenx BV	Anti-il-9 antibodies and methods of use thereof
WO2022262959A1 (en)	2021-06-15	2022-12-22	Astellas Pharma Europe Bv	Bispecific binding agents binding to cldn18.2 and cd3
KR20240022546A (ko)	2021-06-18	2024-02-20	치아타이 티안큉 파마수티컬 그룹 주식회사	항il-36r 항체 및 그의 사용
EP4362977A1 (de)	2021-06-29	2024-05-08	Seagen Inc.	Verfahren zur behandlung von krebs mit einer kombination aus einem nichtfucosylierten anti-cd70-antikörper und einem cd47-antagonisten
WO2023021169A1 (en)	2021-08-20	2023-02-23	Intervet International B.V.	Antibodies and igg fusion proteins with an extended half-life
AR126840A1 (es)	2021-08-20	2023-11-22	Llc «Anabion»	Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta
AR126839A1 (es)	2021-08-20	2023-11-22	Llc «Anabion»	Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
US20240368249A1 (en)	2021-08-20	2024-11-07	Intervet Inc.	Fusion proteins for treating atopic dermatitis
MA64631B1 (fr)	2021-08-20	2024-12-31	Joint Stock Company "Biocad"	Procédé de production de capside modifié de virus adéno-associé
WO2023059112A1 (ko) *	2021-10-06	2023-04-13	주식회사 지앤피바이오사이언스	최적의 재조합 발현 구축물의 개발
TW202334196A (zh)	2021-10-07	2023-09-01	英商阿法克塔生命科學有限公司	Pd-l1結合多肽
EP4412711A1 (de)	2021-10-07	2024-08-14	Avacta Life Sciences Limited	Serumhalbwertszeiterweiterte pd-l1-bindende polypeptide
TW202323282A (zh)	2021-10-15	2023-06-16	美商賽特艾克斯生物製藥公司	可活化之多肽複合物
WO2023064955A1 (en)	2021-10-15	2023-04-20	Cytomx Therapeutics, Inc.	Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
KR20240115809A (ko)	2021-10-15	2024-07-26	싸이톰스 테라퓨틱스, 인크.	활성화 가능한 폴리펩타이드 복합체
AU2022377628A1 (en)	2021-10-29	2024-04-11	Seagen Inc.	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
WO2023077521A1 (en)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023094980A1 (en)	2021-11-23	2023-06-01	Fondazione Toscana Life Sciences	Antibodies to coronavirus
CA3239258A1 (en)	2021-11-25	2023-06-01	Qiang Lv	Anti-siglec-15 antibody and use thereof
GB202118201D0 (en)	2021-12-15	2022-01-26	King S College London	Engineered immune cell
WO2023111157A1 (en)	2021-12-16	2023-06-22	Intervet International B.V.	Caninized and felinized antibodies to human ngf
JP2024546759A (ja)	2021-12-16	2024-12-26	インターベットインターナショナルベー．フェー．	イヌインターロイキン－３１受容体アルファｉｉに対するイヌ化抗体
JP2025500274A (ja)	2021-12-24	2025-01-09	アヴィタイドエルエルシー	Ｃｈ１ドメイン親和性リガンド及びエージェント
WO2023153876A1 (ko)	2022-02-10	2023-08-17	주식회사 아피셀테라퓨틱스	Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
GB202201927D0 (en)	2022-02-14	2022-03-30	Kings College	Artificial microrna construct
TW202342510A (zh)	2022-02-18	2023-11-01	英商Ｒｑ生物科技有限公司	抗體
CN119562971A (zh)	2022-03-25	2025-03-04	法国施维雅药厂	抗gal3抗体和组合物
KR20240163736A (ko)	2022-03-30	2024-11-19	노파르티스 아게	항-나트륨이뇨 펩티드 수용체 1(npr1) 항체를 사용하여 장애를 치료하는 방법
WO2023194913A1 (en)	2022-04-05	2023-10-12	Boehringer Ingelheim Vetmedica Gmbh	Immunogenic composition useful for vaccination against rotavirus
WO2023193239A1 (en)	2022-04-08	2023-10-12	Peter Peizhi Luo	Anti-cd28 antibodies and methods of use thereof
WO2023209177A1 (en)	2022-04-29	2023-11-02	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of using the same
WO2023213960A1 (en)	2022-05-06	2023-11-09	Genmab A/S	Methods of treating cancer with anti-tissue factor antibody-drug conjugates
US11932693B2 (en)	2022-05-12	2024-03-19	BioNTech SE	Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023218243A1 (en)	2022-05-12	2023-11-16	Avacta Life Sciences Limited	Lag-3/pd-l1 binding fusion proteins
CA3258004A1 (en)	2022-06-15	2023-12-21	argenx BV	FCRN/HSA BONDING MOLECULES AND METHODS OF USE
EP4554969A1 (de)	2022-07-15	2025-05-21	Janssen Biotech, Inc.	Material und verfahren zur verbesserten biotechnologischen paarung antigenbindender variabler regionen
WO2024025911A1 (en)	2022-07-29	2024-02-01	Avitide LLC	An affinity agent comprising a ligand that binds vce and comprises seq id no: 1
JP2025528751A (ja)	2022-07-29	2025-09-02	アレクトルエルエルシー	Ｃｄ９８ｈｃ抗原結合ドメイン及びその使用法
CN119497721A (zh)	2022-07-29	2025-02-21	艾莱克特有限责任公司	转铁蛋白受体抗原结合结构域及其用途
WO2024038187A1 (en)	2022-08-19	2024-02-22	Medimmune Limited	Assay for detection of il-33
CN120187741A (zh)	2022-09-09	2025-06-20	瑞普利金公司	亲和剂
AU2023372538A1 (en)	2022-11-03	2025-05-01	Seagen Inc.	Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2024129756A1 (en)	2022-12-13	2024-06-20	Seagen Inc.	Site-specific engineered cysteine antibody drug conjugates
IT202300000924U1 (it)	2023-01-23	2024-12-22	Philomena Dove	Cucitura all-up leggins seamless
WO2024163477A1 (en)	2023-01-31	2024-08-08	University Of Rochester	Immune checkpoint blockade therapy for treating staphylococcus aureus infections
CN121002060A (zh)	2023-02-13	2025-11-21	英特维特国际股份有限公司	犬il-13的犬抗体
EP4665756A1 (de)	2023-02-13	2025-12-24	Intervet International B.V.	Antikörper gegen hunde-il-4
CN121219315A (zh)	2023-03-03	2025-12-26	塞德斯医疗公司	抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体
WO2024194685A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
AU2024240129A1 (en)	2023-03-17	2025-10-09	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
FR3147278A1 (fr)	2023-03-31	2024-10-04	Avacta Life Sciences Limited	Polypeptides de liaison au tnfr2 et procedes d'utilisation
EP4688825A1 (de)	2023-03-31	2026-02-11	AffyXell Therapeutics Co., Ltd.	Tnfr2-bindende polypeptide und verfahren zur verwendung
EP4455161A1 (de)	2023-04-24	2024-10-30	ONO Pharmaceutical Co., Ltd.	Vom menschen abgeleitete antikörper gegen das collapsin response mediator protein 2 (crmp2)
AR132494A1 (es)	2023-04-24	2025-07-02	Merck Sharp & Dohme Llc	Aglutinantes de trop2 y conjugados de estos
IL324469A (en)	2023-05-09	2026-01-01	Astrazeneca Ab	Anti-Pseudomonal bispecific antibodies with modified fc regions and methods of using them
WO2024235175A1 (zh)	2023-05-12	2024-11-21	智泽童康(广州)生物科技有限公司	抗cldn6抗体及其用途
IL324556A (en)	2023-05-19	2026-01-01	Servier Lab	Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
IT202300015579A1 (it)	2023-07-25	2025-01-25	Fond Toscana Life Sciences	Anticorpi contro covid-19 e altri coronavirus umani
TW202521562A (zh)	2023-08-11	2025-06-01	美商默沙東有限責任公司	單價介白素-12(IL-12) 異二聚體Fc蛋白
WO2025036848A1 (en)	2023-08-11	2025-02-20	Wuxi Biologics (Shanghai) Co., Ltd.	Anti-muc16 antibodies and uses thereof
WO2025046393A1 (en)	2023-08-25	2025-03-06	Fondazione Per L’Istituto Oncologico Di Ricerca (Ior)	Reagents against human endogenous retroviruses to target cancer cells
WO2025046298A2 (en)	2023-09-01	2025-03-06	iTeos Belgium SA	Anti-trem2 antibodies and methods of use
EP4530295A3 (de)	2023-09-07	2025-05-28	argenx BV	Fcrn-antagonisten und verfahren zur verwendung
WO2025072888A2 (en)	2023-09-28	2025-04-03	Novavax, Inc.	Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025083076A1 (en)	2023-10-17	2025-04-24	BioNTech SE	Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025082594A1 (en)	2023-10-17	2025-04-24	BioNTech SE	Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025083173A1 (en)	2023-10-17	2025-04-24	Linnane Pharma Ab	Bacterial lon protease domains and their use in therapy
AU2024380169A1 (en)	2023-11-17	2026-05-07	WuXi Biologics Ireland Limited	Anti-muc16 antibodies and uses thereof
IT202300026115A1 (it)	2023-12-06	2025-06-06	Fond Per L’Istituto Oncologico Di Ricerca Ior	Una strategia basata su anticorpi che mira ad erg oncogenico attivato nel cancro alla prostata
WO2025133707A1 (en)	2023-12-19	2025-06-26	Vectory Therapeutics B.V.	Anti-tdp-43 antibodies and uses thereof
WO2025133694A1 (en)	2023-12-20	2025-06-26	argenx BV	Fcrn/hsa-binding molecules and methods of use
WO2025133186A1 (en)	2023-12-22	2025-06-26	OncoC4, Inc.	Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025155877A2 (en)	2024-01-18	2025-07-24	The Regents Of The University Of California	Antibodies binding to pad4 and uses thereof
WO2025155971A1 (en)	2024-01-19	2025-07-24	Immunomic Therapeutics, Inc	Anti-activin receptor 1c (alk-7) receptor antibodies
TW202545992A (zh)	2024-01-23	2025-12-01	中國大陸商上海藥明生物技術有限公司	靶向ｃｄ３、ｃｄ１９及ｃｄ２０之多特異性抗體及其用途
TW202545567A (zh)	2024-01-30	2025-12-01	美商思進公司	抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
WO2025166042A1 (en)	2024-01-31	2025-08-07	Alector Llc	Cd98hc antigen-binding domains and uses therefor
WO2025166040A1 (en)	2024-01-31	2025-08-07	Alector Llc	Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166077A1 (en)	2024-01-31	2025-08-07	Alector Llc	Compositions comprising progranulin and uses thereof
WO2025166045A1 (en)	2024-01-31	2025-08-07	Alector Llc	β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
US20250361320A1 (en)	2024-02-27	2025-11-27	Bristol-Myers Squibb Company	Anti-ceacam5 antibodies and uses thereof
US20250361297A1 (en)	2024-03-12	2025-11-27	Adaptam Therapeutics, S.L.	Anti- siglec-15 binding molecules and methods of use
WO2025196207A1 (en)	2024-03-20	2025-09-25	King's College London	Compositions and methods for use in depleting senescent cells and treating aging
WO2025201659A1 (en)	2024-03-28	2025-10-02	BioNTech SE	Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
EP4635983A1 (de)	2024-04-15	2025-10-22	Ymmunobio AG	Neuartiger antikörper mit spezifischer bindung an nptxr und verwendung davon
WO2025235515A1 (en)	2024-05-07	2025-11-13	Cytomx Therapeutics, Inc.	Activatable polypeptide complex formulations
WO2025264572A1 (en)	2024-06-17	2025-12-26	Alector Llc	Transferrin receptor antigen-binding domains and uses therefor
WO2025261951A1 (en)	2024-06-18	2025-12-26	BioNTech SE	Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
WO2026027944A1 (en)	2024-07-30	2026-02-05	Sairopa B.V.	Anti-sirp alpha antibody formulations and uses thereof
US20260048137A1 (en)	2024-08-16	2026-02-19	Ardeagen Corporation	Anti-mesothelin antibody conjugates and methods of use thereof
WO2026041734A1 (en)	2024-08-22	2026-02-26	Novago Therapeutics Ag	Methods for treating neurological disorders using anti-nogo-a antibodies
WO2026041780A2 (en)	2024-08-23	2026-02-26	BioNTech SE	Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment
WO2026057545A1 (en)	2024-09-10	2026-03-19	Neurimmune Ag	Anti-sting antibodies and methods of use thereof
WO2026057739A1 (en)	2024-09-12	2026-03-19	BioNTech SE	Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment
WO2026088159A1 (en)	2024-10-24	2026-04-30	Imuno Therapeutics	Hla-a2 p53 antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4769326A (en) *	1980-02-29	1988-09-06	The Regents Of The University Of California	Expression linkers
DE3584341D1 (de) *	1984-08-24	1991-11-14	Upjohn Co	Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
DE3431140A1 (de) *	1984-08-24	1986-03-06	Behringwerke Ag, 3550 Marburg	Enhancer fuer eukaryotische expressionssysteme
GB2197321B (en) *	1986-09-12	1990-10-03	Genentech Inc	Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line

1987
- 1987-07-23 GB GB878717430A patent/GB8717430D0/en active Pending
1988
- 1988-07-22 JP JP63506088A patent/JP2505268B2/ja not_active Expired - Lifetime
- 1988-07-22 DE DE8888906008T patent/DE3880468T2/de not_active Expired - Lifetime
- 1988-07-22 EP EP88906008A patent/EP0323997B1/de not_active Expired - Lifetime
- 1988-07-22 WO PCT/GB1988/000602 patent/WO1989001036A1/en not_active Ceased
- 1988-07-22 AT AT88906008T patent/ATE88501T1/de not_active IP Right Cessation
1994
- 1994-09-02 US US08/300,063 patent/US5591639A/en not_active Expired - Lifetime
1996
- 1996-04-16 US US08/633,013 patent/US5658759A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0323997A1 (de)	1989-07-19
GB8717430D0 (en)	1987-08-26
JP2505268B2 (ja)	1996-06-05
US5658759A (en)	1997-08-19
WO1989001036A1 (en)	1989-02-09
JPH02500330A (ja)	1990-02-08
DE3880468T2 (de)	1993-09-09
EP0323997B1 (de)	1993-04-21
DE3880468D1 (de)	1993-05-27
US5591639A (en)	1997-01-07

Legal Events

Date	Code	Title
1993-10-15	UEP	Publication of translation of european patent specification
1998-11-15	EEIH	Change in the person of patent owner
2003-04-15	EEIH	Change in the person of patent owner
2008-10-15	EELA	Cancelled due to lapse of time

Publication	Publication Date	Title
DE3880468D1 (de)	1993-05-27	Rekombinante dns-expressionsvektoren.
EP0266190A3 (en)	1989-10-25	Expression of protein c
DE68922917D1 (de)	1995-07-13	KEX2-Endoprotease und Verfahren zu ihrer Herstellung.
ES2013324A6 (es)	1990-05-01	Un metodo mejorado para producir una proteina heterologa.
IL77081A0 (en)	1986-04-29	Cloned human erythropoietin genes and products thereof
EP0092182A3 (en)	1984-07-18	Preparation of functional human urokinase proteins
ATE93272T1 (de)	1993-09-15	Expression von protein c.
GB2147585B (en)	1990-12-12	Cdna clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity and/or mast cell growth factor activity
MY101971A (en)	1992-02-29	Cdna clones coding for polypeptides exhibiting human granulocyte macrophage and eosinophil cellular growth factor activity.
AU600253B2 (en)	1990-08-09	Expression of eucaryotic proteins
EP0182448A3 (de)	1987-10-28	Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
GB2171703B (en)	1989-11-15	Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
IL74537A0 (en)	1985-06-30	Novel expression plasmids containing the full cdna sequence of calf prochymosin